<SEC-DOCUMENT>0001193125-24-202430.txt : 20240819
<SEC-HEADER>0001193125-24-202430.hdr.sgml : 20240819
<ACCEPTANCE-DATETIME>20240819060459
ACCESSION NUMBER:		0001193125-24-202430
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240815
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240819
DATE AS OF CHANGE:		20240819

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AN2 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001880438
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				820606654
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41331
		FILM NUMBER:		241218175

	BUSINESS ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027
		BUSINESS PHONE:		(650) 331-9090

	MAIL ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d879523d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:antx="http://www.an2therapeutics.com/20240815" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-347">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-08-15_to_2024-08-15">0001880438</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2024-08-15_to_2024-08-15" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2024-08-15_to_2024-08-15">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="antx-20240815.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-08-15_to_2024-08-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880438</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-15</xbrli:startDate> <xbrli:endDate>2024-08-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880438</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-15</xbrli:startDate> <xbrli:endDate>2024-08-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001880438</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-15</xbrli:startDate> <xbrli:endDate>2024-08-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-375">8-K</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt:datemonthdayyearen" id="ixv-376">August&#160;15, 2024</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (date of earliest event reported)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-377">AN2 THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as specified in its charter)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:stateprovnameen" id="ixv-378">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-379">001-41331</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-380">82-0606654</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:49%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-381">1800 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-382">Suite D</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-383">Menlo Park</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:stateprovnameen" id="ixv-384">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-385">94027</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip code)</span></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code): <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-386">(650)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-387">331-9090</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-388">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-389">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-390">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-391">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-392">Common Stock, $0.00001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" id="ixv-393">ANTX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen" id="ixv-394">The Nasdaq Global Select Market</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-size:10pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" id="ixv-395">Series A Junior Participating Preferred Stock, par value $0.00001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-size:0.5pt;color:#FFFFFF"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" id="ixv-396">ANTX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-size:0.5pt;color:#FFFFFF"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" format="ixt-sec:exchnameen" id="ixv-397">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-398">&#9746;</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-08-15_to_2024-08-15" format="ixt-sec:boolballotbox" id="ixv-399">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth under &#8220;Item 3.03 Material Modification to Rights of Security Holders&#8221; of this Current Report on Form <span style="white-space:nowrap">8-K</span> with respect to the entry into a Rights Agreement is incorporated into this Item 1.01 by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;3.03.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Material Modification to Rights of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;15, 2024, AN2 Therapeutics, Inc. (the &#8220;<span style="font-style:italic">Company</span>&#8221;) entered into a Rights Agreement between the Company and Equiniti Trust Company, LLC as Rights Agent (as amended from time to time, the &#8220;<span style="font-style:italic">Rights Agreement</span>&#8221;) that was previously approved by the Board of Directors of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Rights Agreement, a dividend was declared of one preferred stock purchase right (individually, a &#8220;<span style="font-style:italic">Right</span>&#8221; and collectively, the &#8220;<span style="font-style:italic">Rights</span>&#8221;) for each share of common stock, par value $0.00001 per share (the &#8220;<span style="font-style:italic">Common Stock</span>&#8221;), of the Company outstanding at the close of business on August&#160;29, 2024 (the &#8220;<span style="font-style:italic">Record Date</span>&#8221;). Each Right will entitle the registered holder thereof, after the Rights become exercisable and until August&#160;15, 2025 (or the earlier redemption, exchange or termination of the Rights), to purchase from the Company one <span style="white-space:nowrap">one-thousandth</span> of a share of Series A Junior Participating Preferred Stock, par value $0.00001 per share (the &#8220;<span style="font-style:italic">Series A Preferred</span>&#8221;), of the Company at a price of $6.50 per one <span style="white-space:nowrap">one-thousandth</span> of a share of Series A Preferred (the &#8220;<span style="font-style:italic">Purchase Price</span>&#8221;). Until the earlier to occur of (i)&#160;the close of business on the tenth business day following a public announcement that a person or group of </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliated or associated persons has acquired, or obtained the right to acquire, beneficial ownership of 20%<sup style="font-size:75%; vertical-align:top"> </sup>or more of the Common Stock (an &#8220;<span style="font-style:italic">Acquiring Person</span>&#8221;) or (ii)&#160;the close of business on the tenth business day (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) following the commencement or announcement of an intention to make a tender offer or exchange offer the consummation of which would result in a person or group becoming an Acquiring Person (the earlier of (i)&#160;and (ii) being called the &#8220;<span style="font-style:italic">Distribution Date</span>&#8221;), the Rights will be evidenced, with respect to any of the Common Stock certificates outstanding as of the Record Date, by such Common Stock certificates, or, with respect to any uncertificated Common Stock registered in book entry form, by notation in book entry, in either case together with a copy of the Summary of Rights attached as Exhibit C to the Rights Agreement. Under the Rights Agreement, synthetic ownership of Common Stock in the form of derivative securities counts towards the ownership threshold, to the extent actual shares of Common Stock equivalent to the economic exposure created by the derivative security are directly or indirectly beneficially owned by a counterparty to such derivative security. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights Agreement provides that any person who beneficially owned 20%<sup style="font-size:75%; vertical-align:top"> </sup>or more of the Common Stock immediately prior to the first public announcement of the adoption of the Rights Agreement, together with any affiliates and associates of that person (each an &#8220;<span style="font-style:italic">Existing Holder</span>&#8221;), shall not be deemed to be an &#8220;Acquiring Person&#8221; for purposes of the Rights Agreement unless an Existing Holder becomes the beneficial owner of one or more additional shares of Common Stock (other than pursuant to a dividend or distribution paid or made by the Company on the outstanding Common Stock in Common Stock or pursuant to a split or subdivision of the outstanding Common Stock) and upon acquiring such additional shares, the Existing Holder beneficially owns 20%<sup style="font-size:75%; vertical-align:top"> </sup>or more of the Common Stock then outstanding or if the Existing Holder exchanges synthetic ownership of Common Stock to another form of beneficial ownership (other than pursuant to the express terms of a written agreement as it existed immediately prior to the first public announcement of the Rights Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights will be transferred only with the Common Stock until the Distribution Date (or earlier redemption, exchange, termination or expiration of the Rights). As soon as practicable following the Distribution Date, separate certificates evidencing the Rights (&#8220;<span style="font-style:italic">Right Certificates</span>&#8221;) will be mailed to holders of record of the Common Stock as of the close of business on the Distribution Date and such separate Right Certificates alone will evidence the Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights are not exercisable until the Distribution Date. The Rights will expire on August&#160;15, 2025, subject to the Company&#8217;s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. The Rights will at no time have any voting rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A Preferred purchasable upon exercise of the Rights will be entitled, when, as and if declared, to a minimum preferential quarterly dividend payment of $1.00 per share or, if greater, an aggregate dividend of 1,000 times the dividend, if any, declared per share of Common Stock. In the event of liquidation, dissolution or winding up of the Company, the holders of the Series A Preferred will be entitled to a minimum preferential liquidation payment of $1,000 per share (plus any accrued but unpaid dividends), provided that such holders of the Series A Preferred will be entitled to an aggregate payment of 1,000 times the payment made per </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share of Common Stock. Each share of Series A Preferred will have 1,000 votes and will vote together with the Common Stock. Finally, in the event of any merger, consolidation or other transaction in which shares of the Common Stock are exchanged, each share of Series A Preferred will be entitled to receive 1,000 times the amount received per share of Common Stock. The Series A Preferred will not be redeemable. The Rights are protected by customary anti-dilution provisions. Because of the nature of the Series A Preferred&#8217;s dividend and liquidation rights, the value of one <span style="white-space:nowrap">one-thousandth</span> of a share of Series A Preferred purchasable upon exercise of each Right should approximate the value of one share of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Price payable, and the number of one <span style="white-space:nowrap">one-thousandths</span> of a share of Series A Preferred or other securities or property issuable, upon exercise of the Rights are subject to adjustment from time to time to prevent dilution (i)&#160;in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Series A Preferred, (ii)&#160;upon the grant to holders of the Series A Preferred of certain rights or warrants to subscribe for or purchase Series A Preferred or convertible securities at less than the current market price of the Series A Preferred or (iii)&#160;upon the distribution to holders of the Series A Preferred of evidences of indebtedness, cash, securities or assets (excluding regular periodic cash dividends at a rate not in excess of 125% of the rate of the last regular periodic cash dividend theretofore paid or, in case regular periodic cash dividends have not theretofore been paid, at a rate not in excess of 50% of the average net income per share of the Company for the four quarters ended immediately prior to the payment of such dividend, or dividends payable in shares of Series A Preferred (which dividends will be subject to the adjustment described in clause (i)&#160;above)) or of subscription rights or warrants (other than those referred to above). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a person becomes an Acquiring Person or if the Company were the surviving corporation in a merger with an Acquiring Person or any affiliate or associate of an Acquiring Person and shares of the Common Stock were not changed or exchanged in such merger, each holder of a Right, other than Rights that are or were acquired or beneficially owned by the Acquiring Person (which Rights will thereafter be void), will thereafter have the right to receive upon exercise that number of shares of Common Stock having a market value of two times the then current Purchase Price of one Right. In the event that, after a person has become an Acquiring Person, the Company were acquired in a merger or other business combination transaction or more than 50% of its assets or earning power were sold, proper provision shall be made so that each holder of a Right shall thereafter have the right to receive, upon the exercise thereof at the then current Purchase Price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction would have a market value of two times the then current Purchase Price of one Right. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after a person becomes an Acquiring Person and prior to the earlier of one of the events described in the last sentence of the previous paragraph or the acquisition by such Acquiring Person of 50% or more of the then outstanding Common Stock, the Board of Directors may cause the Company to exchange the Rights (other than Rights owned by an Acquiring Person which have become void), in whole or in part, for shares of Common Stock at an exchange rate of one share of Common Stock per Right (subject to adjustment). </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No adjustment in the Purchase Price will be required until cumulative adjustments require an adjustment of at least 1% in such Purchase Price. No fractional shares of Series A Preferred or Common Stock will be issued (other than fractions of Series A Preferred which are integral multiples of one <span style="white-space:nowrap">one-thousandth</span> of a share of Series A Preferred, which may, at the election of the Company, be evidenced by depository receipts), and in lieu thereof, a payment in cash will be made based on the market price of the Series A Preferred or Common Stock on the last trading date prior to the date of exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights may be redeemed in whole, but not in part, at a price of $0.01 per Right (the &#8220;<span style="font-style:italic">Redemption Price</span>&#8221;) by the Board of Directors at any time prior to the time that an Acquiring Person has become such. The redemption of the Rights may be made effective at such time, on such basis and with such conditions as the Board of Directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder of the Company beyond those as an existing stockholder, including, without limitation, the right to vote or to receive dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the provisions of the Rights Agreement may be amended by the Board of Directors of the Company, or a duly authorized committee thereof, for so long as the Rights are then redeemable, and after the Rights are no longer redeemable, the Company may amend or supplement the Rights Agreement in any manner that does not adversely affect the interests of the holders of the Rights (other than an Acquiring Person or any affiliate or associate of an Acquiring Person). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Right will be distributed to stockholders of the Company for each share of Common Stock owned of record by them on August&#160;29, 2024. As long as the Rights are attached to the Common Stock, the Company will issue one Right with each new share of Common Stock so that all such shares will have attached Rights. The Company has agreed that, from and after the Distribution Date, the Company will reserve 500,000 shares of Series A Preferred initially for issuance upon exercise of the Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights are designed to assure that all of the Company&#8217;s stockholders receive fair and equal treatment in the event of any proposed takeover of the Company and to guard against partial tender offers, open market accumulations and other abusive or coercive tactics to gain control of the Company without paying all stockholders a control premium. The Rights will cause substantial dilution to a person or group that acquires 20% or more of the Common Stock on terms not approved by the Company&#8217;s Board of Directors. The Rights should not interfere with any merger or other business combination approved by the Board of Directors at any time prior to the first date that a person or group has become an Acquiring Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Designations establishing the terms of the Series A Preferred, the Rights Agreement specifying the terms of the Rights and the text of the press release announcing the declaration of the Rights are incorporated herein by reference as exhibits to this registration statement. The foregoing summary of the Rights Agreement is qualified in its entirety by reference to such exhibits. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent applicable, the information set forth under &#8220;Item 3.03 Material Modification to Rights of Security Holders&#8221; of this Current Report on Form <span style="white-space:nowrap">8-K</span> with respect to the Certificate of Designations and Series A Junior Participating Preferred Stock is incorporated into this Item 5.03 by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Exhibits</span>. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d879523dex31.htm">Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on August&#160;15, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d879523dex41.htm">Rights Agreement, dated as of August&#160;15, 2024, between AN2 Therapeutics, Inc. and Equiniti Trust Company, LLC, which includes the Form of Certificate of Designations of Series A Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit&#160;B and the Summary of Rights to Purchase Preferred Stock as Exhibit C. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d879523dex991.htm">Press Release of AN2 Therapeutics, Inc., dated August&#160;16, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:46%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">AN2 Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: August&#160;19, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Easom</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Eric Easom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer and Director</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d879523dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF
DESIGNATIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SERIES A
JUNIOR PARTICIPATING PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">AN2 THERAPEUTICS, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant
to Section&nbsp;151 of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delaware General Corporation Law) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AN2 Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called
the &#147;<I>Corporation</I>&#148;), hereby certifies that the following resolution was adopted by the Board of Directors of the Corporation (hereinafter called the &#147;<I>Board of Directors</I>&#148; or the &#147;<I>Board</I>&#148;) as required
by Section&nbsp;151 of the General Corporation Law at a meeting duly called and held on August&nbsp;15, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">RESOLVED, that pursuant to
the authority expressly granted to and vested in the Board in accordance with the provisions of the Amended and Restated Certificate of Incorporation of the Corporation, the Board hereby creates a series of Preferred Stock, par value $0.00001 per
share (the &#147;<I>Preferred Stock</I>&#148;), of the Corporation and hereby states the designation and number of shares, and fixes the relative rights, powers and preferences, and qualifications, limitations and restrictions thereof as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Designation and Amount</U>. The shares of such series shall be designated as &#147;Series A Junior Participating
Preferred Stock&#148; (the &#147;<I>Series A Preferred</I>&#148;) and the number of shares constituting the Series A Preferred shall be 500,000. Such number of shares may be increased or decreased by resolution of the Board of Directors;
<B><I>provided,</I></B> that no decrease shall reduce the number of shares of Series A Preferred to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options,
rights or warrants or upon the conversion of any outstanding securities issued by the Corporation convertible into Series A Preferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Dividends and Distributions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Subject to the prior and superior rights of the holders of any shares of any class or series of stock of this Corporation
ranking prior and superior to the Series A Preferred with respect to dividends, the holders of shares of Series A Preferred, in preference to the holders of Common Stock, par value $0.00001 per share (the &#147;<I>Common Stock</I>&#148;), of the
Corporation, and of any other stock ranking junior to the Series A Preferred, shall be entitled to receive, when, as and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash on the
first day of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
March, June, September and December in each year (each such date being referred to herein as a &#147;<I>Quarterly Dividend Payment Date</I>&#148;), commencing on the first Quarterly Dividend
Payment Date after the first issuance of a share or fraction of a share of Series A Preferred, in an amount per share (rounded to the nearest cent) equal to the greater of (a) $1.00 or (b)&nbsp;subject to the provision for adjustment hereinafter set
forth, 1,000 times the aggregate per share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends or other distributions, other than a dividend
payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date or, with respect to the
first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series A Preferred. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common
Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common
Stock, then in each such case the amount to which holders of shares of Series A Preferred were entitled immediately prior to such event under clause (b)&nbsp;of the preceding sentence shall be adjusted by multiplying such amount by a fraction, the
numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Corporation shall declare a dividend or distribution on the Series A Preferred as provided in paragraph (A)&nbsp;of
this <U>Section</U><U></U><U>&nbsp;2</U> immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock); provided that, in the event no dividend or distribution shall have been
declared on the Common Stock during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, a dividend of $1.00 per share on the Series A Preferred shall nevertheless be payable when, as and if
declared by the Board of Directors, in accordance with paragraph (A)&nbsp;above on such subsequent Quarterly Dividend Payment Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Dividends shall begin to accrue and be cumulative on outstanding shares of Series A Preferred from the Quarterly Dividend
Payment Date next preceding the date of issue of such shares, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such shares shall begin to accrue from the
date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series A Preferred entitled to receive a quarterly dividend and before
such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue and be cumulative from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends paid on the shares of
Series A Preferred in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-by-share</FONT></FONT> basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A
Preferred entitled to receive payment of a dividend or distribution declared thereon, which record date shall be not more than sixty (60)&nbsp;days prior to the date fixed for the payment thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Voting Rights</U>. The holders of shares of Series A Preferred shall have
the following voting rights: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Subject to the provision for adjustment hereinafter set forth, each share of Series A
Preferred shall entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the shareholders of the Corporation. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of
Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of
Common Stock, then in each such case the number of votes per share to which holders of shares of Series A Preferred were entitled immediately prior to such event shall be adjusted by multiplying such number by a fraction, the numerator of which is
the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Except as otherwise provided herein, in any other Certificate of Designations creating a series of Preferred Stock or any
similar stock, or by law, the holders of shares of Series A Preferred and the holders of shares of Common Stock and any other capital stock of the Corporation having general voting rights shall vote together as one class on all matters submitted to
a vote of shareholders of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Except as set forth herein, or as otherwise provided by law, holders of
Series A Preferred shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) If, at the time of any annual meeting of stockholders for the election of directors, the equivalent of six quarterly
dividends (whether or not consecutive) payable on any share or shares of Series A Preferred are in default, the number of directors constituting the Board of Directors of the Corporation shall be increased by two. In addition to voting together with
the holders of Common Stock for the election of other directors of the Corporation, the holders of record of the Series A Preferred, voting separately as a class to the exclusion of the holders of Common Stock, shall be entitled at such meeting of
stockholders (and at each subsequent annual meeting of stockholders), unless all dividends in arrears on the Series A Preferred have been paid or declared and set apart for payment prior thereto, to vote for the election of two directors of the
Corporation, the holders of any Series A Preferred being entitled to cast a number of votes per share of Series A Preferred as is specified in paragraph (A)&nbsp;of this <U>Section</U><U></U><U>&nbsp;3</U>. Each such additional director shall serve
until the next annual meeting of stockholders for the election of directors, or until his successor shall be elected and shall qualify, or until his right to hold such office terminates pursuant to the provisions of this
<U>Section</U><U></U><U>&nbsp;3(D)</U>. Until the default in payments of all dividends which permitted the election of said directors shall cease to exist, any director who shall have been so elected pursuant to the provisions of this
<U>Section</U><U></U><U>&nbsp;3(D)</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
may be removed at any time, without cause, only by the affirmative vote of the holders of the shares of Series A Preferred at the time entitled to cast a majority of the votes entitled to be cast
for the election of any such director at a special meeting of such holders called for that purpose, and any vacancy thereby created may be filled by the vote of such holders. If and when such default shall cease to exist, the holders of the Series A
Preferred shall be divested of the foregoing special voting rights, subject to revesting in the event of each and every subsequent like default in payments of dividends. Upon the termination of the foregoing special voting rights, the terms of
office of all persons who may have been elected directors pursuant to said special voting rights shall forthwith terminate, and the number of directors constituting the Board of Directors shall be reduced by two. The voting rights granted by this
<U>Section</U><U></U><U>&nbsp;3(D)</U> shall be in addition to any other voting rights granted to the holders of the Series A Preferred in this <U>Section</U><U></U><U>&nbsp;3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Certain Restrictions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Whenever quarterly dividends or other dividends or distributions payable on the Series A Preferred as provided in
<U>Section</U><U></U><U>&nbsp;2</U> are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series A Preferred outstanding shall have been paid in full, the Corporation shall
not: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) declare or pay dividends, or make any other distributions, on any shares of stock ranking junior (either as to
dividends or upon liquidation, dissolution or winding up) to the Series A Preferred; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) declare or pay dividends, or
make any other distributions, on any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred, except dividends paid ratably on the Series A Preferred and all such parity
stock on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) redeem or purchase or otherwise acquire for consideration shares of any stock ranking junior (either as to dividends or
upon liquidation, dissolution or winding up) to the Series A Preferred, provided that the Corporation may at any time redeem, purchase or otherwise acquire shares of any such junior stock in exchange for shares of any stock of the Corporation
ranking junior (both as to dividends and upon dissolution, liquidation or winding up) to the Series A Preferred; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
redeem or purchase or otherwise acquire for consideration any shares of Series A Preferred, or any shares of stock ranking on a parity with the Series A Preferred, except in accordance with a purchase offer made in writing or by publication (as
determined by the Board of Directors) to all holders of such shares upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and
classes, shall determine in good faith will result in fair and equitable treatment among the respective series or classes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Corporation shall not permit any subsidiary of the Corporation to
purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (A)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4</U>, purchase or otherwise acquire such shares at such time and in
such manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Reacquired Shares</U>. Any shares of Series A Preferred purchased or otherwise acquired by the
Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of Preferred Stock and may be reissued as part of a new
series of Preferred Stock subject to the conditions and restrictions on issuance set forth herein, in the Amended and Restated Certificate of Incorporation of the Corporation or in any other Certificate of Designations creating a series of Preferred
Stock or any similar stock or as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Liquidation, Dissolution or Winding Up</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Upon any liquidation, dissolution or winding up of the Corporation, voluntary or otherwise no distribution shall be made
(i)&nbsp;to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Preferred unless, prior thereto, the holders of Series A Preferred shall have received an amount per
share (the &#147;<I>Series A Preferred Liquidation Preference</I>&#148;) equal to $1,000 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment, provided that
the holders of shares of Series A Preferred shall be entitled to receive an aggregate amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the aggregate amount to be distributed per share to holders
of Common Stock, or (ii)&nbsp;to the holders of shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred, except distributions made ratably on the Series A Preferred and
all such parity stock in proportion to the total amounts to which the holders of all such shares are entitled upon such liquidation, dissolution or winding up. In the event the Corporation shall at any time declare or pay any dividend on the Common
Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or
lesser number of shares of Common Stock, then in each such case the aggregate amount to which holders of Series A Preferred were entitled immediately prior to such event under the proviso in clause (i)&nbsp;of the preceding sentence shall be
adjusted by multiplying such amount by a fraction the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that are outstanding
immediately prior to such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) In the event, however, that there are not sufficient assets available to permit
payment in full of the Series A Preferred Liquidation Preference and the liquidation preferences of all other classes and series of stock of the Corporation, if any, that rank on a parity with the Series A Preferred in respect thereof, then the
assets available for such distribution shall be distributed ratably to the holders of the Series A Preferred and the holders of such parity shares in proportion to their respective liquidation preferences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Neither the merger or consolidation of the Corporation into or with
another corporation nor the merger or consolidation of any other corporation into or with the Corporation shall be deemed to be a liquidation, dissolution or winding up of the Corporation within the meaning of this
<U>Section</U><U></U><U>&nbsp;6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Consolidation, Merger, etc</U>. In case the Corporation shall enter into any
consolidation, merger, combination or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case each share of Series A Preferred shall at
the same time be similarly exchanged or changed into an amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in
kind), as the case may be, into which or for which each share of Common Stock is changed or exchanged. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a
subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each
such case the amount set forth in the preceding sentence with respect to the exchange or change of shares of Series A Preferred shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Common
Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>No Redemption</U>. The Series A Preferred shall not be redeemable by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Rank</U>. The Series A Preferred shall rank, with respect to the payment of dividends and the distribution of assets upon
liquidation, dissolution or winding up, junior to all series of any other class of the Corporation&#146;s Preferred Stock, except to the extent that any such other series specifically provides that it shall rank on a parity with or junior to the
Series A Preferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Amendment</U>. At any time any shares of Series A Preferred are outstanding, the Amended and
Restated Certificate of Incorporation of the Corporation shall not be further amended in any manner which would materially alter or change the powers, preferences or special rights of the Series A Preferred so as to affect them adversely without the
affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of Series A Preferred, voting separately as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Fractional Shares</U>. Series A Preferred may be issued in fractions of a share that shall entitle the holder, in
proportion to such holder&#146;s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series A Preferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, AN2 Therapeutics, Inc. has caused this certificate to be executed
on behalf of the Corporation by the undersigned authorized officer this August&nbsp;15, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Easom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Eric Easom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: President&nbsp;&amp; CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Certificate of Designation</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d879523dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AN2 Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Equiniti Trust Company, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as
Rights Agent </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rights Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of August&nbsp;15, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RIGHTS AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Rights Agreement, dated as of August&nbsp;15, 2024 (this &#147;<I>Agreement</I>&#148;), between AN2 Therapeutics, Inc., a Delaware corporation
(the &#147;<I>Company</I>&#148;), and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent (the &#147;<I>Rights Agent</I>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on
August&nbsp;15, 2024, the Board of Directors (the &#147;<I>Board</I>&#148;) of the Company adopted this Agreement, and has authorized and declared a dividend of one preferred stock purchase right (a &#147;<I>Right</I>&#148;) for each share of Common
Stock (as defined in <U>Section</U><U></U><U>&nbsp;1.6</U>) of the Company outstanding at the close of business on August&nbsp;29, 2024 (the &#147;<I>Record Date</I>&#148;) and has authorized and directed the issuance of one Right (subject to
adjustment as provided herein) with respect to each share of Common Stock that shall become outstanding between the Record Date and the earliest of the Distribution Date and the Expiration Date (as such terms are defined in <U>Sections 3.1</U> and
<U>7.1</U>, respectively), each Right initially representing the right to purchase one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> (subject to adjustment) of a share of Series A Junior Participating Preferred Stock, par value $0.00001 per
share (the &#147;<I>Series A Preferred</I>&#148;), of the Company having the rights, powers and preferences set forth in the form of Certificate of Designations of Series A Junior Participating Preferred Stock<B></B>&nbsp;attached hereto as
<U>Exhibit A</U> (as amended from time to time), upon the terms and subject to the conditions hereinafter set forth; <I>provided, however,</I> that Rights may be issued with respect to Common Stock that shall become outstanding after the
Distribution Date and prior to the Expiration Date in accordance with <U>Section</U><U></U><U>&nbsp;22</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Certain
Definitions</U>. For purposes of this Agreement, the following terms have the meanings indicated: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1. &#147;<I>Acquiring
Person</I>&#148; shall mean any Person who or which, together with all Related Persons of such Person,<B></B>&nbsp;shall&nbsp;be the Beneficial Owner of 20% or more of the Common Stock then outstanding, but shall not include (i)<B></B>&nbsp;an
Exempt Person or (ii)&nbsp;any Existing Holder, unless and until such time as such Existing Holder shall, after the first public announcement of this Agreement, (x)&nbsp;become the Beneficial Owner of one or more additional shares of Common Stock
(other than pursuant to a dividend or distribution paid or made by the Company on the outstanding Common Stock in Common Stock or pursuant to a split or subdivision of the outstanding Common Stock), unless upon acquiring such Beneficial Ownership,
such Existing Holder does not Beneficially Own 20% or more of the Common Stock then outstanding or (y)&nbsp;become the Beneficial Owner of any share of Common Stock pursuant to clauses 1.3.1 through 1.3.4 of the definition of Beneficial Ownership
below that such Person Beneficially Owned as of the first public announcement of this Agreement pursuant to clause 1.3.5 of the definition of Beneficial Ownership below, unless (a)&nbsp;such Beneficial Ownership is acquired pursuant to the express
terms of a written agreement as it existed at the time of the first public announcement of this Agreement or (b)&nbsp;upon acquiring such Beneficial Ownership, such Existing Holder does not Beneficially Own pursuant to clauses 1.3.1 through 1.3.4 of
the definition of Beneficially Ownership 20% or more of the Common Stock then outstanding. Notwithstanding the foregoing, no Person shall become </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an &#147;Acquiring Person&#148; as the result of an acquisition of Common Stock by the Company which, by
reducing the number of shares outstanding, increases the proportionate number of shares Beneficially Owned by such Person to 20%<B> </B>or more of the Common Stock then outstanding; <I>provided, however</I>, that if a Person shall become the
Beneficial Owner of 20% or more of the Common Stock then outstanding solely by reason of share purchases by the Company and shall, after such share purchases by the Company, become the Beneficial Owner of one or more additional shares of Common
Stock (other than pursuant to a dividend or distribution paid or made by the Company on the outstanding Common Stock in Common Stock or pursuant to a split or subdivision of the outstanding Common Stock), then such Person shall be deemed to be an
&#147;Acquiring Person&#148; unless, upon becoming the Beneficial Owner of such additional Common Stock, such Person does not Beneficially Own 20%&nbsp;or more of the Common Stock then outstanding. Notwithstanding the foregoing, if the Board
determines in good faith that a Person who would otherwise be an &#147;Acquiring Person,&#148; as defined pursuant to the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;1.1</U>, has become such inadvertently (including, without
limitation, because (A)&nbsp;such Person was unaware that it Beneficially Owned a percentage of Common Stock that would otherwise cause such Person to be an &#147;Acquiring Person&#148; or (B)&nbsp;such Person was aware of the extent of its
Beneficial Ownership of Common Stock but had no actual knowledge of the consequences of such Beneficial Ownership under this Agreement) and had no intention of changing or influencing control of the Company, then such Person shall not be deemed to
be or have become an &#147;Acquiring Person&#148; at any time for any purposes of this Agreement unless and until such Person shall have failed to divest as promptly as practicable (as determined, in good faith, by the Board) a sufficient number of
shares of Common Stock so that such Person would no longer be an Acquiring Person, as defined pursuant to the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;1.1</U>. For all purposes of this Agreement, any calculation of the number of
shares of Common Stock outstanding at any particular time, including for purposes of determining the particular percentage of such outstanding Common Stock of which any Person is the Beneficial Owner, shall include the number of shares of Common
Stock not outstanding at the time of such calculation that such Person is otherwise deemed to Beneficially Own for purposes of this Agreement. The number of shares of Common Stock not outstanding that such Person is otherwise deemed to Beneficially
Own for purposes of this Agreement shall be deemed to be outstanding for the purpose of computing the percentage of the outstanding number of shares of Common Stock owned by such Person but shall not be deemed to be outstanding for the purpose of
computing the percentage of outstanding Common Stock owned by any other Person. Notwithstanding the foregoing, if any Person satisfying the requirements of Rule <FONT STYLE="white-space:nowrap">13d-1(b)(1)</FONT> (other than a Person that so
satisfies Rule <FONT STYLE="white-space:nowrap">13d-1(b)(1)</FONT> solely by reason of Rule <FONT STYLE="white-space:nowrap">13d-1(b)(1)(ii)(E))</FONT> who would otherwise be an &#147;Acquiring Person&#148; has become so as a result of its actions
in the ordinary course of such Person&#146;s business as a derivatives dealer, then such Person shall not be deemed to be or have become an &#147;Acquiring Person&#148; at any time for any purposes of this Agreement unless and until the Board
determines, in good faith, that such actions were taken with the intent or effect of evading or assisting any other Person to evade the purposes and intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2. &#147;<I>Affiliate</I>&#148; and &#147;<I>Associate</I>&#148; shall have the respective meanings ascribed to such terms in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the &#147;<I>Exchange Act</I>&#148;), as in effect on the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3. A Person shall be deemed the &#147;<I>Beneficial Owner</I>&#148; of and shall be deemed to &#147;<I>Beneficially Own</I>&#148; or have
<I>&#147;</I><I>Beneficial Ownership</I><I>&#148;</I> of any securities: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.1. which such Person or any of such Person&#146;s Related Persons, directly or
indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (A)&nbsp;voting power, which includes the power to vote, or to direct the voting of, such security (except that a Person shall not be deemed to
be the Beneficial Owner of any security under this <U>clause</U><U></U><U>&nbsp;(A)</U> if such voting power arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to,
and in accordance with, Section&nbsp;14(a) of the Exchange Act by means of a solicitation statement filed on Schedule 14A), and/or (B)&nbsp;investment power, which includes the power to dispose, or to direct the disposition of, such security; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.2. which such Person or any of such Person&#146;s Related Persons, directly or indirectly, has the Right to Acquire; <I>provided,
however</I>, that a Person shall not be deemed the Beneficial Owner of, or to Beneficially Own, (x)&nbsp;securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person&#146;s Related Persons,
until such tendered securities are accepted for purchase or exchange, (y)&nbsp;securities which such Person or any of such Person&#146;s Related Persons, has a Right to Acquire upon the exercise of Rights at any time prior to the time that any
Person becomes an Acquiring Person, or (z)&nbsp;securities issuable upon the exercise of Rights from and after the time that any Person becomes an Acquiring Person if such Rights were acquired by such Person or any of such Person&#146;s Related
Persons prior to the Distribution Date or pursuant to <U>Section</U><U></U><U>&nbsp;3.1</U> or <U>Section</U><U></U><U>&nbsp;22</U> (&#147;<I>Original Rights</I>&#148;) or pursuant to <U>Section</U><U></U><U>&nbsp;11.9</U> or
<U>Section</U><U></U><U>&nbsp;11.15</U> with respect to an adjustment to Original Rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.3. which are Beneficially Owned, directly
or indirectly, by any other Person (or any Affiliate or Associate thereof) with whom such Person or any of such Person&#146;s Related Persons,<B> </B>has an agreement, arrangement or understanding to act together for the purpose of acquiring,
holding, voting or disposing of any securities of the Company (except that a Person shall not be deemed to be the Beneficial Owner of any security under this <U>Section</U><U></U><U>&nbsp;1.3.3</U> if such voting power arises solely from a revocable
proxy or consent given to such Person in response to a public proxy or consent solicitation made pursuant to, and in accordance with, Section&nbsp;14(a) of the Exchange Act by means of a solicitation statement filed on Schedule 14A); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.4. which such Person would otherwise be deemed to be the beneficial owner pursuant to Rule <FONT STYLE="white-space:nowrap">13d-3</FONT>
or <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.5. which are &#147;Beneficially Owned&#148; (within the
meaning of <U>Sections 1.3.1</U> through <I><U></U></I><U>1.3.4<I></I></U><I></I> hereof), directly or indirectly, by a Counterparty (as such term is defined in the immediately following paragraph) (or any of such Counterparty&#146;s Affiliates or
Associates) that has any Synthetic Equity Position (as such term is defined in the immediately following paragraph) (without regard to any short or similar position under the same or any other Synthetic Equity Position) to which such Person or any
of such Person&#146;s Affiliates or Associates is a Receiving Party (as such term is defined in the immediately following paragraph) and that is not otherwise included in the definition of Beneficial Ownership (within the meaning of <U>Sections
1.3.1</U> through <U>1.3.4</U> hereof); <I>provided</I>, <I>however</I>, that the number of shares of Common Stock of the Company that a Person is deemed to &#147;Beneficially Own&#148; pursuant to this <U>Section&nbsp;1.3.5</U> in connection with a
particular Synthetic Equity Position shall not exceed the number of Notional Common Shares (as such term is defined in the immediately following paragraph) with respect to such Synthetic Equity Position; <I>provided</I><I>&nbsp;further</I>, that the
number of securities Beneficially Owned by each Counterparty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including its Affiliates and Associates) under a Synthetic Equity Position shall for purposes of this clause <U>Section&nbsp;1.3.5</U> be deemed to include all securities that are Beneficially
Owned, directly or indirectly, by any other Counterparty (or any of such other Counterparty&#146;s Affiliates or Associates) under any Synthetic Equity Position to which such first Counterparty (or any of such first Counterparty&#146;s Affiliates or
Associates) is a Receiving Party, with this proviso being applied to successive Counterparties as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A &#147;<I>Synthetic
Equity Position</I>&#148; is a &#147;derivative security&#148; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">16a-1(c)</FONT> under the Exchange Act) between two parties (the &#147;<I>Receiving Party</I>&#148; and the
&#147;<I>Counterparty</I>&#148;) that constitutes a &#147;call equivalent position&#148; (as such term is defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act); <I>provided</I> that, for the purposes of the
definition of &#147;Synthetic Equity Position,&#148; the term &#147;derivative security&#148; shall also include any security or instrument that would not otherwise constitute a &#147;derivative security&#148; as a result of any feature that would
make any conversion, exercise or similar right or privilege of such security or instrument become determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into
which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination. The number of shares of Common Stock of the
Company specified or referenced in such derivative security contract (as determined by the Board in good faith) is the number of &#147;<I>Notional Common Shares</I>.&#148; For the avoidance of doubt, interests in broad-based index options,
broad-based index futures and broad-based publicly traded market baskets of stocks approved for trading by the appropriate federal governmental authority shall not be deemed to be Synthetic Equity Positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No Person shall be deemed to be the &#147;Beneficial Owner&#148; of, to have &#147;Beneficial Ownership&#148; of or to &#147;Beneficially
Own&#148; any securities which such Person or any of such Person&#146;s Related Persons would otherwise be deemed to &#147;Beneficially Own&#148; pursuant to this <U>Section</U><U></U><U>&nbsp;1.3</U> solely as a result of any merger or other
acquisition agreement between the Company and such Person (or one or more of such Person&#146;s Related Persons) or the consummation of any transactions contemplated thereby, or any tender, voting or support agreement entered into by such Person (or
one or more of such Person&#146;s Related Persons) in connection therewith or the consummation of any transactions contemplated thereby, if, prior to such Person becoming an Acquiring Person, the Board has approved such merger or other acquisition
agreement, or such tender, voting or support agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No Person who is an officer, director or employee of an Exempt Person shall be
deemed, solely by reason of such Person&#146;s status or authority as such, to be the &#147;Beneficial Owner&#148; of, to have &#147;Beneficial Ownership&#148; of or to &#147;Beneficially Own&#148; any securities that are &#147;Beneficially
Owned&#148; (as defined in this <U>Section</U><U></U><U>&nbsp;1.3</U>), including, without limitation, in a fiduciary capacity, by an Exempt Person or by any other such officer, director or employee of an Exempt Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4. &#147;<I>Business Day</I>&#148; shall mean any day other than a Saturday, Sunday, or a day on which banking institutions in the State of
New York are authorized or obligated by law or executive order to close. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5. &#147;<I>close of business</I>&#148; on any given date shall mean 5:00 p.m., New York
time, on such date; <I>provided, however,</I> that if such date is not a Business Day it shall mean 5:00 p.m., New York time, on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6. &#147;<I>Common Stock</I>&#148; when used with reference to the Company shall mean the Common Stock, par value $0.00001 per share, of the
Company. &#147;Common Stock&#148; when used with reference to any Person other than the Company shall mean the capital stock with the greatest voting power, or the equity securities or other equity interest having power to control or direct the
management of, such other Person or, if such Person is a Subsidiary of another Person, the Person or Persons which ultimately control such first-mentioned Person, and which has issued and outstanding such capital stock, equity securities or equity
interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7. &#147;<I>Exempt Person</I>&#148; shall mean the Company, any Subsidiary of the Company, in each case including, without
limitation, the officers and members of the board of directors thereof acting in their fiduciary capacities, or any employee benefit plan of the Company or of any Subsidiary of the Company or any entity or trustee holding (or acting in a fiduciary
capacity in respect of) shares of capital stock of the Company for or pursuant to the terms of any such plan, or for the purpose of funding other employee benefits for employees of the Company or any Subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8. &#147;<I>Existing Holder</I>&#148; shall mean any Person who, immediately prior to the first public announcement of the adoption of this
Agreement, is the Beneficial Owner of 20% or more of the Common Stock then outstanding, together with any Affiliates and Associates of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.9. &#147;<I>Person</I>&#148; shall mean any individual, partnership, joint venture, limited liability company, firm, corporation,
unincorporated association or organization, trust or other entity, and shall include any successor (by merger or otherwise) of any such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.10. &#147;<I>Related Person</I>&#148; shall mean, as to any Person, any Affiliates or Associates of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.11. &#147;<I>Right to Acquire</I>&#148; shall mean a legal, equitable or contractual right to acquire (whether directly or indirectly and
whether exercisable immediately, or only after the passage of time, compliance with regulatory requirements, fulfillment of a condition or otherwise), pursuant to any agreement, arrangement or understanding, whether or not in writing (excluding
customary agreements entered into in good faith with and between an underwriter and selling group members in connection with a firm commitment underwriting registered under the Securities Act of 1933, as amended (the &#147;<I>Securities
Act</I>&#148;)), or upon the exercise of any option, warrant or right, through conversion of a security, pursuant to the power to revoke a trust, discretionary account or similar arrangement, pursuant to the power to terminate a repurchase or
similar <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;stock borrowing&#148; agreement or arrangement, or pursuant to the automatic termination of a trust, discretionary account or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.12. &#147;<I>Stock Acquisition Date</I>&#148; shall mean the first date of public announcement (which, for purposes of this definition,
shall include, without limitation, the filing of a report pursuant to Section&nbsp;13(d) of the Exchange Act or pursuant to a comparable successor statute) by the Company or an Acquiring Person that an Acquiring Person has become such or that
discloses information which reveals the existence of an Acquiring Person or such earlier date as a majority of the Board shall become aware of the existence of an Acquiring Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.13. &#147;<I>Subsidiary</I>&#148; of any Person shall mean any partnership, joint venture,
limited liability company, firm, corporation, unincorporated association, trust or other entity of which a majority of the voting power of the voting equity securities or equity interests is owned, of record or beneficially, directly or indirectly,
by such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.14. A &#147;<I>Trigger Event</I>&#148; shall be deemed to have occurred upon any Person becoming an Acquiring Person.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.15. The following terms shall have the meanings defined for such terms in the Sections set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Section</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book Entry Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">call equivalent position</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">common stock equivalent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparty</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">current per share market price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">derivative security</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">equivalent preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>27.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expiration Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final Expiration Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notional Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Original Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receiving Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemption Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemption Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>23.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights Agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spread</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Substitution Period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.1.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summary of Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Synthetic Equity Position</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.3.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trading Day</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.4.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>27.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>27.1</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Appointment of Rights Agent</U>. The Company hereby appoints the Rights
Agent to act as rights agent for the Company and the holders of the Rights (who, in accordance with <U>Section</U><U></U><U>&nbsp;3</U>, shall prior to the Distribution Date also be the holders of the Common Stock) in accordance with the terms and
conditions hereof, and the Rights Agent hereby accepts such appointment. The Company may from time to time appoint such <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents as it may deem necessary or desirable. In the event the Company appoints
one or more <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agents, the respective duties of the Rights Agent and any <FONT STYLE="white-space:nowrap">co-Rights</FONT> Agent shall be as the Company shall determine. Contemporaneously with such
appointment, if any, the Company shall notify the Rights Agent thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Issuance of Right Certificates</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1. <U>Rights Evidenced by Stock Certificates</U>. Until the earlier of (i)&nbsp;the close of business on the tenth (10<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after the Stock Acquisition Date or (ii)&nbsp;the close of business on the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after the date of the
commencement of, or first public announcement of the intent of any Person (other than an Exempt Person) to commence, a tender or exchange offer the consummation of which would result in any Person becoming an Acquiring Person (the earlier of
(i)&nbsp;and (ii) being herein referred to as the &#147;<I>Distribution Date</I>&#148;), (x) the Rights (unless earlier expired, redeemed or terminated) will be evidenced (subject to the provisions of <U>Section</U><U></U><U>&nbsp;3.2</U>) by the
certificates representing the Common Stock registered in the names of the holders thereof or, in the case of uncertificated shares of Common Stock registered in book entry form (&#147;<I>Book Entry Shares</I>&#148;), by notation in book entry (which
certificates for Common Stock and Book Entry Shares shall also be deemed to be Right Certificates) and not by separate certificates, and (y)&nbsp;the Rights (and the right to receive certificates therefor) will be transferable only in connection
with the transfer of the underlying Common Stock. The preceding sentence notwithstanding, prior to the occurrence of a Distribution Date specified as a result of an event described in clause (ii) (or such later Distribution Date as the Board may
select pursuant to this sentence), the Board may postpone, one or more times, the Distribution Date which would occur as a result of an event described in clause (ii)&nbsp;beyond the date set forth in such clause (ii). As soon as practicable after
the Distribution Date, the Company will prepare and execute, the Rights Agent will countersign and the Company (or, if requested, the Rights Agent) will send, by first-class, postage-prepaid mail, to each record holder of Common Stock as of the
close of business on the Distribution Date (other than any Acquiring Person or any Related Person of an Acquiring Person), at the address of such holder shown on the records of the Company or the transfer agent or registrar for the Common Stock, one
or more certificates for Rights, in substantially the form of <U>Exhibit B</U> hereto (a &#147;<I>Right Certificate</I>&#148;), evidencing one Right (subject to adjustment as provided herein) for each share of Common Stock so held. As of and after
the Distribution Date, the Rights will be evidenced solely by such Right Certificates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2. <U>Summary of Rights</U>. On the Record Date or as soon as practicable thereafter, the
Company will send or cause to be sent a copy of a Summary of Rights to Purchase Series A Preferred, in substantially the form attached hereto as <U>Exhibit C</U> (the &#147;<I>Summary of Rights</I>&#148;), by first-class, postage-prepaid mail, to
each record holder of Common Stock as of the close of business on the Record Date (other than any Acquiring Person or any Related Person of any Acquiring Person) at the address of such holder shown on the records of the Company or the transfer agent
or registrar for the Common Stock. Any failure to send a copy of the Summary of Rights shall not invalidate the Rights or affect their transfer with the Common Stock. With respect to certificates representing Common Stock and Book Entry Shares
outstanding as of the close of business on the Record Date, until the Distribution Date (or the earlier Expiration Date), the Rights will be evidenced by such certificates for Common Stock registered in the names of the holders thereof or Book Entry
Shares, as applicable, together with a copy of the Summary of Rights and the registered holders of the Common Stock shall also be registered holders of the associated Rights. Until the Distribution Date (or the earlier Expiration Date), the
surrender for transfer of any certificate for Common Stock or Book Entry Shares outstanding at the close of business on the Record Date, with or without a copy of the Summary of Rights, shall also constitute the transfer of the Rights associated
with the Common Stock represented thereby and the Book Entry Shares, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3. <U>New Certificates and Uncertificated Shares
After Record Date</U>. Certificates for Common Stock that become outstanding (whether upon issuance out of authorized but unissued Common Stock, disposition out of treasury or transfer or exchange of outstanding Common Stock or otherwise) after the
Record Date but prior to the earliest of the Distribution Date or the Expiration Date, or in certain circumstances provided in <U>Section</U><U></U><U>&nbsp;22</U> hereof, after the Distribution Date, shall have impressed, printed, stamped, written
or otherwise affixed onto them a legend in substantially the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">This certificate also evidences and entitles the holder
hereof to certain rights as set forth in a Rights Agreement between AN2 Therapeutics, Inc. (the &#147;<I>Company</I>&#148;) and Equiniti Trust Company, LLC, as Rights Agent, dated as of August&nbsp;15, 2024, as the same may be amended from time to
time (the &#147;<I>Agreement</I>&#148;), the terms of which are hereby incorporated herein by reference and a copy of which is on file at the principal executive offices of the Company. Under certain circumstances, as set forth in the Agreement,
such Rights (as defined in the Agreement) will be evidenced by separate certificates and will no longer be evidenced by this certificate. The Company will mail to the holder of this certificate a copy of the Agreement without charge after receipt of
a written request therefor. <B><I>As described in the Agreement, Rights which are owned by, transferred to or have been owned by Acquiring Persons (as defined in the Agreement) or any Related Person (as defined in the </I></B><B><I>Agreement) of any
Acquiring Person shall become null and void and will no longer be transferable</I></B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to any Book Entry Shares, such legend shall be included in a notice to the record holder of
such shares in accordance with applicable law. Until the Distribution Date (or the earlier Expiration Date), the Rights associated with the Common Stock represented by such certificates and such Book Entry Shares shall be evidenced solely by such
certificates or the Book Entry Shares alone, and the surrender for transfer of any such certificates or Book Entry Shares, except as otherwise provided herein, shall also constitute the transfer of the Rights associated with the Common Stock
represented thereby. In the event that the Company purchases or otherwise acquires any Common Stock after the Record Date but prior to the Distribution Date, any Rights associated with such Common Stock shall be deemed canceled and retired so that
the Company shall not be entitled to exercise any Rights associated with the Common Stock that are no longer outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding
this <U>Section</U><U></U><U>&nbsp;3.3</U>, neither the omission of the legend required hereby, nor the failure to provide the notice thereof, shall affect the enforceability of any part of this Agreement or the rights of any holder of the Rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Form of Right Certificates</U>. The Right Certificates (and the forms of election to purchase shares and assignment,
including the certifications therein, to be printed on the reverse thereof) shall each be substantially in the form set forth in <U>Exhibit B</U> hereto and may have such marks of identification or designation and such legends, summaries or
endorsements printed thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply with any applicable law or with any rule or regulation made pursuant thereto or with
any rule or regulation of any stock exchange or trading system on which the Rights may from time to time be listed or quoted, or to conform to usage. Subject to the terms and conditions hereof, the Right Certificates, whenever issued, shall be dated
as of the Record Date, and shall show the date of countersignature by the Rights Agent, and on their face shall entitle the holders thereof to purchase such number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A
Preferred as shall be set forth therein at the price per one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred set forth therein (the &#147;<I>Purchase Price</I>&#148;), but the number of such <FONT
STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred and the Purchase Price shall be subject to adjustment as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Countersignature and Registration</U>. The Right Certificates shall be executed on behalf of the Company by the Chief
Executive Officer, the Chief Financial Officer and the Chief Legal Officer of the Company, either manually or by facsimile signature, and shall have affixed thereto the Company&#146;s seal or a facsimile thereof which shall be attested by the
Secretary or any Assistant Secretary of the Company or by such officers as the Board may designate, either manually or by facsimile signature. The Right Certificates shall be countersigned, either manually or by facsimile signature, by an authorized
signatory of the Rights Agent, but it shall not be necessary for the same signatory to countersign all of the Right Certificates hereunder. No Right Certificate shall be valid for any purpose unless so countersigned. In case any officer of the
Company who shall have signed any of the Right Certificates shall cease to be such officer of the Company before countersignature by the Rights Agent and issuance and delivery by the Company, such Right Certificates, nevertheless, may be
countersigned by the Rights Agent, and issued and delivered by the Company with the same force and effect as though the Person who signed such Right Certificates had not ceased to be such officer of the Company; and any Right Certificate may be
signed on behalf of the Company by any Person who, at the actual date of the execution of such Right Certificate, shall be a proper officer of the Company to sign such Right Certificate, although at the date of the execution of this Agreement any
such Person was not such an officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Following the Distribution Date, the Rights Agent will keep or cause to be kept, at its
principal office, books for registration and transfer of the Right Certificates issued hereunder. Such books shall show the names and addresses of the respective holders of the Right Certificates, the number of Rights evidenced on its face by each
of the Right Certificates, the certificate number of each of the Right Certificates and the date of each of the Right Certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Transfer, Split Up, Combination and Exchange of Right Certificates; Mutilated, Destroyed, Lost or Stolen Right
Certificates</U>. Subject to the provisions of this Agreement, including but not limited to <U>Section</U><U></U><U>&nbsp;11.1.2</U> and <U>Section</U><U></U><U>&nbsp;14</U>, at any time after the close of business on the Distribution Date, and at
or prior to the close of business on the Expiration Date, any Right Certificate or Right Certificates (other than Right Certificates representing Rights that have become void pursuant to <U>Section</U><U></U><U>&nbsp;11.1.2</U> or that have been
exchanged pursuant to <U>Section</U><U></U><U>&nbsp;27</U>) may be transferred, split up, combined or exchanged for another Right Certificate or Right Certificates, entitling the registered holder to purchase a like number of <FONT
STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred as the Right Certificate or Right Certificates surrendered then entitled such holder to purchase. Any registered holder desiring to transfer, split up, combine or
exchange any Right Certificate shall make such request in writing delivered to the Rights Agent, and shall surrender, together with any required form of assignment and certificate duly executed and properly completed, the Right Certificate or Right
Certificates to be transferred, split up or combined or exchanged at the office of the Rights Agent designated for such purpose. Neither the Rights Agent nor the Company shall be obligated to take any action whatsoever with respect to the transfer
of any such surrendered Right Certificate or Right Certificates until the registered holder shall have properly completed and duly executed the certificate contained in the form of assignment on the reverse side of such Right Certificate or Right
Certificates and shall have provided such additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) thereof or any Related Person of such registered holder or such Beneficial Owner (or such former Beneficial Owner), in
each case, as the Company shall reasonably request. Thereupon, the Rights Agent shall countersign and deliver to the Person entitled thereto a Right Certificate or Right Certificates, as the case may be, as so requested. The Company may require
payment from the holders of Right Certificates of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer, split up or combination or exchange of such Right Certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of <U>Section</U><U></U><U>&nbsp;11.1.2</U>, at any time after the Distribution Date and prior to the Expiration
Date, upon receipt by the Company and the Rights Agent of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of a Right Certificate, and, in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to them, and, at the Company&#146;s request, reimbursement to the Company and the Rights Agent of all reasonable expenses incidental thereto, and upon surrender to the Rights Agent and cancellation of the Right Certificate if mutilated,
the Company will make and deliver a new Right Certificate of like tenor to the Rights Agent for countersignature and delivery to the registered owner in lieu of the Right Certificate so lost, stolen, destroyed or mutilated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Exercise of Rights; Purchase Price; Expiration Date of Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1. <U>Exercise of Rights</U>. Subject to <U>Section</U><U></U><U>&nbsp;11.1.2</U> and except as otherwise provided herein, the registered
holder of any Right Certificate may exercise the Rights evidenced thereby in whole or in part at any time after the Distribution Date upon surrender of the Right Certificate, with the form of election to purchase and certification on the reverse
side thereof properly completed and duly executed, to the Rights Agent at the office of the Rights Agent designated for such purpose, together with payment of the aggregate Purchase Price for the total number of
<FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred (or other securities, cash or other assets) as to which the Rights are exercised, at or prior to the time (the &#147;<I>Expiration Date</I>&#148;) that is the
earliest of (i)&nbsp;the close of business on August&nbsp;15, 2025 (the &#147;<I>Final Expiration Date</I>&#148;), (ii) the time at which the Rights are redeemed as provided in <U>Section</U><U></U><U>&nbsp;23</U> (the &#147;<I>Redemption
Date</I>&#148;), (iii) the closing of any merger or other acquisition transaction involving the Company pursuant to an agreement of the type described in <U>Section</U><U></U><U>&nbsp;13.3</U> at which time the Rights are deemed terminated, or
(iv)&nbsp;the time at which the Rights are exchanged as provided in <U>Section</U><U></U><U>&nbsp;27</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2. <U>Purchase</U>. The
Purchase Price for each one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred pursuant to the exercise of a Right shall be initially $6.50, shall be subject to adjustment from time to time as provided in
<U>Sections 11, 13</U> and <U>26</U> and shall be payable in lawful money of the United States of America in accordance with <U>Section</U><U></U><U>&nbsp;7.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3. <U>Payment Procedures</U>. Except as otherwise provided herein, upon receipt of a Right Certificate representing exercisable Rights, with
the form of election to purchase and certification properly completed and duly executed, accompanied by payment of the aggregate Purchase Price for the total number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A
Preferred to be purchased and an amount equal to any applicable tax or charge required to be paid by the holder of such Right Certificate in accordance with <U>Section</U><U></U><U>&nbsp;9</U>, in cash or by certified or cashier&#146;s check or
money order payable to the order of the Company, the Rights Agent shall thereupon promptly (i)(A) requisition from any transfer agent of the Series A Preferred (or make available, if the Rights Agent is the transfer agent) certificates for the
number of shares of Series A Preferred to be purchased and the Company hereby irrevocably authorizes its transfer agent to comply with all such requests, or (B)&nbsp;if the Company shall have elected to deposit the total number of shares of Series A
Preferred issuable upon exercise of the Rights hereunder with a depositary agent, requisition from such depositary agent depositary receipts representing interests in such number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share
of Series A Preferred as are to be purchased (in which case certificates for the Series A Preferred represented by such receipts shall be deposited by the transfer agent with the depositary agent) and the Company hereby directs such depositary agent
to comply with all such requests; (ii)&nbsp;when appropriate, requisition from the Company the amount of cash to be paid in lieu of the issuance of fractional shares in accordance with <U>Section</U><U></U><U>&nbsp;14</U> or otherwise in accordance
with <U>Section</U><U></U><U>&nbsp;11.1.3</U>; (iii) promptly after receipt of such certificates or depositary receipts, cause the same to be delivered to the registered holder of such Right Certificate, or upon the order of the registered holder of
such Right Certificate, registered in such name or names as may be designated by such holder and (iv)&nbsp;when appropriate, after receipt, promptly deliver such cash to the registered holder of such Right Certificate, or upon the order of the
registered holder of such Right Certificate, to such other Person as designated by such holder. In the event that the Company is obligated to issue other securities of the Company, pay cash and/or distribute other property pursuant to
<U>Section</U><U></U><U>&nbsp;11.1.3</U>, the Company will make all arrangements necessary so that such other securities, cash and/or other property are available for distribution by the Rights Agent, if and when appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4. <U>Partial Exercise</U>. In case the registered holder of any Right Certificate shall
exercise less than all the Rights evidenced thereby, a new Right Certificate evidencing Rights equivalent to the Rights remaining unexercised shall be issued by the Rights Agent and delivered to the registered holder of such Right Certificate or to
his or her duly authorized assigns, subject to the provisions of <U>Section</U><U></U><U>&nbsp;14</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5. <U>Full Information
Concerning Ownership</U>. Notwithstanding anything in this Agreement to the contrary, neither the Rights Agent nor the Company shall be obligated to undertake any action with respect to a registered holder of Rights upon the occurrence of any
purported transfer or exercise of Rights pursuant to <U>Section</U><U></U><U>&nbsp;6</U> or as set forth in this <U>Section</U><U></U><U>&nbsp;7</U> unless the certification contained in the form of election to purchase set forth on the reverse side
of the Right Certificate surrendered for such exercise shall have been properly completed and duly executed by the registered holder thereof and the Company shall have been provided with such additional evidence of the identity of the Beneficial
Owner (or former Beneficial Owner) thereof or any Related Person of such registered holder or such Beneficial Owner (or such former Beneficial Owner), in each case, as the Company shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Cancellation and Destruction of Right Certificates</U>. All Right Certificates surrendered for the purpose of exercise,
transfer, split up, combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Rights Agent for cancellation or in canceled form, or, if surrendered to the Rights Agent, shall be canceled by it, and no
Right Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Rights Agent for cancellation and retirement, and the Rights Agent shall so cancel and
retire, any other Right Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. Subject to applicable law and regulation, the Rights Agent shall maintain in a retrievable database electronic records or physical
records of all cancelled or destroyed Rights Certificates which have been cancelled or destroyed by the Rights Agent. The Rights Agent shall maintain such electronic records or physical records for the time period required by applicable law and
regulation. Upon written request of the Company (and at the expense of the Company), the Rights Agent shall provide to the Company or its designee copies of such electronic records or physical records relating to Rights Certificates cancelled or
destroyed by the Rights Agent.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Reservation and Availability of Capital Stock</U>. The Company covenants and agrees
that, from and after the Distribution Date, it will cause to be reserved and kept available out of its authorized and unissued Series A Preferred (and, following the occurrence of a Trigger Event, out of its authorized and unissued Common Stock or
other securities or out of its shares held in its treasury) the number of shares of Series A Preferred (and, following the occurrence of a Trigger Event, Common Stock and/or other securities) that will be sufficient to permit the exercise in full of
all outstanding Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">So long as the Series A Preferred (and, following the occurrence of a Trigger Event, Common
Stock and/or other securities) issuable upon the exercise of Rights may be listed on the NASDAQ Global Select Market (&#147;<I>NASDAQ</I>&#148;) or any other national securities exchange or traded in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, the Company shall use its best efforts to cause, from and after such time as the Rights become exercisable, all shares reserved for such issuance to be listed or admitted to trading
on the NASDAQ or such other exchange or market upon official notice of issuance upon such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees that
it will take all such action as may be necessary to ensure that all Series A Preferred (and, following the occurrence of a Trigger Event, Common Stock and/or other securities) delivered upon exercise of Rights shall, at the time of delivery of the
certificates for such shares (subject to payment of the Purchase Price), be duly and validly authorized and issued and fully paid and nonassessable shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From and after such time as the Rights become exercisable, the Company shall use its best efforts, if then necessary, to permit the issuance
of Series A Preferred upon the exercise of Rights, to register and qualify such Series A Preferred under the Securities Act and any applicable state securities or &#147;Blue Sky&#148; laws (to the extent exemptions therefrom are not available),
cause such registration statement and qualifications to become effective as soon as possible after such filing and keep such registration and qualifications effective until the earlier of the date as of which the Rights are no longer exercisable for
such securities and the Expiration Date. The Company may temporarily suspend, from time to time for a period of time not to exceed one hundred twenty (120)&nbsp;days in any particular instance, the exercisability of the Rights in order to prepare
and file a registration statement under the Securities Act and permit it to become effective or in order to prepare and file any supplement or amendment to such registration statement that the Board determines to be necessary and appropriate under
applicable law. Upon any such suspension, the Company shall issue a public announcement stating that the exercisability of the Rights has been temporarily suspended, as well as a public announcement at such time as the suspension is no longer in
effect. Notwithstanding any provision of this Agreement to the contrary, the Rights shall not be exercisable in any jurisdiction unless the requisite qualification or exemption in such jurisdiction shall have been obtained and until a registration
statement under the Securities Act (if required) shall have been declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company further covenants and agrees that it
will pay when due and payable any and all taxes and charges which may be payable in respect of the issuance or delivery of the Right Certificates or of any Series A Preferred (or Common Stock and/or other securities, as the case may be) upon the
exercise of Rights. The Company shall not, however, be required to pay any tax or charge which may be payable in respect of any transfer or delivery of Right Certificates to a Person other than, or the issuance or delivery of certificates for the
Series A Preferred (or Common Stock and/or other securities, as the case may be) in a name other than that of, the registered holder of the Right Certificate evidencing Rights surrendered for exercise or to issue or deliver any certificates for
Series A Preferred (or Common Stock and/or other securities, as the case may be) in a name other than that of the registered holder upon the exercise of any Rights until any such tax or charge shall have been paid (any such tax or charge being
payable by the registered holder of such Right Certificate at the time of surrender) or until it has been established to the Company&#146;s satisfaction that no such tax or charge is due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Series A Preferred Record Date</U>. Each Person in whose name any
certificate for Series A Preferred (or Common Stock and/or other securities, as the case may be) is issued upon the exercise of Rights shall for all purposes be deemed to have become the holder of record of the Series A Preferred (or Common Stock
and/or other securities, as the case may be) represented thereby on, and such certificate shall be dated, the date upon which the Right Certificate evidencing such Rights was duly surrendered and payment of the Purchase Price (and any applicable
taxes or charges) was made; <I>provided, however,</I> that if the date of such surrender and payment is a date upon which the Series A Preferred (or Common Stock and/or other securities, as the case may be) transfer books of the Company are closed,
such Person shall be deemed to have become the record holder of such shares (fractional or otherwise) on, and such certificate shall be dated, the next succeeding Business Day on which the Series A Preferred (or Common Stock and/or other securities,
as the case may be) transfer books of the Company are open. Prior to the exercise of the Rights evidenced thereby (or an exchange pursuant to <U>Section</U><U></U><U>&nbsp;27</U>), the holder of a Right Certificate shall not be entitled to any
rights of a holder of Series A Preferred (or Common Stock or other securities, as the case may be) for which the Rights shall be exercisable, including, without limitation, the right to vote or to receive dividends or other distributions, and shall
not be entitled to receive any notice of any proceedings of the Company, except as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Adjustment of
Purchase Price, Number of Shares or Number of Rights</U>. The Purchase Price, the number of shares of Series A Preferred or other securities or property purchasable upon exercise of each Right and the number of Rights outstanding are subject to
adjustment from time to time as provided in this <U>Section</U><U></U><U>&nbsp;11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1. <U>Post-Execution Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.1. <U>Corporate Dividends, Reclassifications, Etc</U>. In the event the Company shall, at any time after the date of this Agreement,
(A)&nbsp;declare and pay a dividend on the Series A Preferred payable in Series A Preferred, (B)&nbsp;subdivide the outstanding Series A Preferred, (C)&nbsp;combine the outstanding Series A Preferred into a smaller number of shares of Series A
Preferred or (D)&nbsp;issue any shares of its capital stock in a reclassification of the Series A Preferred (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing or surviving
corporation), except as otherwise provided in this <U>Section</U><U></U><U>&nbsp;11.1.1</U>, the Purchase Price in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination or reclassification,
and the number and kind of shares of capital stock issuable on such date, shall be proportionately adjusted so that the holder of any Right exercised after such time shall be entitled to receive the aggregate number and kind of shares of capital
stock which, if such Right had been exercised immediately prior to such date and at a time when the Series A Preferred transfer books of the Company were open, such holder would have owned upon such exercise and been entitled to receive by virtue of
such dividend, subdivision, combination or reclassification; <I>provided, however,</I> that in no event shall the consideration to be paid upon the exercise of one Right be less than the aggregate par value of the shares of capital stock of the
Company issuable upon exercise of one Right. If an event occurs which would require an adjustment under both <U>Section</U><U></U><U>&nbsp;11.1.1</U> and <U>Section</U><U></U><U>&nbsp;11.1.2</U>, the adjustment provided for in this
<U>Section</U><U></U><U>&nbsp;11.1.1</U> shall be in addition to, and shall be made prior to, the adjustment required pursuant to, <U>Section</U><U></U><U>&nbsp;11.1.2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.2. <U>Acquiring Person Events; Triggering Events</U>. Subject to
<U>Section</U><U></U><U>&nbsp;27</U>, in the event that a Trigger Event occurs, then, from and after the first occurrence of such event, each holder of a Right, except as provided below, shall thereafter have a right to receive, upon exercise
thereof at a price per Right equal to the then current Purchase Price multiplied by the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred for which a Right is then exercisable (without giving effect
to this <U>Section</U><U></U><U>&nbsp;11.1.2</U>), in accordance with the terms of this Agreement and in lieu of Series A Preferred, such number of shares of Common Stock as shall equal the result obtained by (x)&nbsp;multiplying the then current
Purchase Price by the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred for which a Right is then exercisable (without giving effect to this <U>Section</U><U></U><U>&nbsp;11.1.2</U>) and
(y)&nbsp;dividing that product by 50% of the current per share market price of the Common Stock (determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) on the first of the date of the occurrence of, or the date of the first public
announcement of, a Trigger Event (the &#147;<I>Adjustment Shares</I>&#148;); <I>provided</I> that the Purchase Price and the number of Adjustment Shares shall thereafter be subject to further adjustment as appropriate in accordance with
<U>Section</U><U></U><U>&nbsp;11.6</U>. Notwithstanding the foregoing, upon and after the occurrence of a Trigger Event, any Rights that are or were acquired or Beneficially Owned by (1)&nbsp;any Acquiring Person or any Related Person of such
Acquiring Person, (2)&nbsp;a transferee of any Acquiring Person (or of any Related Person of such Acquiring Person) who becomes a transferee after the Acquiring Person becomes such, or (3)&nbsp;a transferee of any Acquiring Person (or of any Related
Person of such Acquiring Person) who becomes a transferee prior to or concurrently with the Acquiring Person becoming such and receives such Rights pursuant to either (A)&nbsp;a transfer (whether or not for consideration) from the Acquiring Person
to holders of equity interests in such Acquiring Person or to any Person with whom the Acquiring Person has any continuing agreement, arrangement or understanding regarding the transferred Rights or (B)&nbsp;a transfer which the Board has determined
is part of a plan, arrangement or understanding which has as a primary purpose or effect avoidance of this <U>Section</U><U></U><U>&nbsp;11.1.2</U>, and subsequent transferees, shall become void without any further action, and any holder (whether or
not such holder is an Acquiring Person or a Related Person of an Acquiring Person) of such Rights shall thereafter have no right to exercise such Rights under any provision of this Agreement or otherwise. From and after the Trigger Event, no Right
Certificate shall be issued pursuant to <U>Section</U><U></U><U>&nbsp;3</U> or <U>Section</U><U></U><U>&nbsp;6</U> that represents Rights that are or have become void pursuant to the provisions of this paragraph, and any Right Certificate delivered
to the Rights Agent that represents Rights that are or have become void pursuant to the provisions of this paragraph shall be canceled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company shall use all reasonable efforts to ensure that the provisions of this <U>Section</U><U></U><U>&nbsp;11.1.2</U> are complied with,
but shall have no liability to any holder of Right Certificates or any other Person as a result of its failure to make any determinations with respect to any Acquiring Person or its Related Persons or transferees hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">From and after the occurrence of an event specified in <U>Section</U><U></U><U>&nbsp;13.1</U>, any Rights that theretofore have not been
exercised pursuant to this <U>Section</U><U></U><U>&nbsp;11.1.2</U> shall thereafter be exercisable only in accordance with <U>Section</U><U></U><U>&nbsp;13</U> and not pursuant to this <U>Section</U><U></U><U>&nbsp;11.1.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.3. <U>Insufficient Shares</U>. The Company may at its option substitute for Common Stock issuable upon the exercise of Rights in
accordance with the foregoing <U>Section</U><U></U><U>&nbsp;11.1.2</U> a number of shares of Series A Preferred or fraction thereof such that the then current per share market price of one share of Series A Preferred multiplied by such number or
fraction is equal to the then current per share market price of one share of Common Stock. In the event that upon the occurrence of a Trigger Event there shall not be sufficient Common Stock authorized but unissued, or held by the Company as
treasury shares, to permit the exercise in full of the Rights in accordance with the foregoing <U>Section</U><U></U><U>&nbsp;11.1.2</U>, the Company shall take all such action as may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary to authorize additional Common Stock for issuance upon exercise of the Rights, <I>provided, however,</I> that if the Company determines that it is unable to cause the authorization of a
sufficient number of additional shares of Common Stock, then, in the event the Rights become exercisable, the Company, with respect to each Right and to the extent necessary and permitted by applicable law and any agreements or instruments in effect
on the date hereof to which it is a party, shall: (A)&nbsp;determine the excess of (1)&nbsp;the value of the Adjustment Shares issuable upon the exercise of a Right (the &#147;<I>Current Value</I>&#148;), over (2)&nbsp;the Purchase Price (such
excess, the &#147;<I>Spread</I>&#148;) and (B)&nbsp;with respect to each Right (other than Rights which have become void pursuant to <U>Section</U><U></U><U>&nbsp;11.1.2</U>), make adequate provision to substitute for the Adjustment Shares, upon
payment of the applicable Purchase Price, (1)&nbsp;cash, (2) a reduction in the Purchase Price, (3)&nbsp;Series A Preferred, (4)&nbsp;other equity securities of the Company (including, without limitation, shares, or fractions of shares, of preferred
stock which, by virtue of having dividend, voting and liquidation rights substantially comparable to those of the Common Stock, the Board has deemed in good faith to have substantially the same value as the Common Stock) (each such share of
preferred stock or fractions of shares of preferred stock constituting a &#147;<I>common stock equivalent</I>&#148;)), (5) debt securities of the Company, (6)&nbsp;other assets or (7)&nbsp;any combination of the foregoing having an aggregate value
equal to the Current Value, where such aggregate value has been determined by the Board based upon the advice of a nationally recognized investment banking firm selected in good faith by the Board; <I>provided, however,</I> that if the Company shall
not have made adequate provision to deliver value pursuant to clause (B)&nbsp;above within thirty (30)&nbsp;days following the occurrence of a Trigger Event, then the Company shall be obligated to deliver, to the extent necessary and permitted by
applicable law and any agreements or instruments in effect on the date hereof to which it is a party, upon the surrender for exercise of a Right and without requiring payment of the Purchase Price, Common Stock (to the extent available) and then, if
necessary, such number or fractions of Series A Preferred (to the extent available) and then, if necessary, cash, which shares and/or cash have an aggregate value equal to the Spread. If, upon the occurrence of a Trigger Event, the Board shall
determine in good faith that it is likely that sufficient additional shares of Common Stock could be authorized for issuance upon exercise in full of the Rights, then, if the Board so elects, the thirty (30)&nbsp;day period set forth above, may be
extended to the extent necessary, but not more than one hundred twenty (120)&nbsp;days following the occurrence of a Trigger Event, in order that the Company may seek stockholder approval for the authorization of such additional shares (such thirty
(30)&nbsp;day period, as it may be extended, is herein called the &#147;<I>Substitution Period</I>&#148;). To the extent that the Company determines that some actions need be taken pursuant to the second and/or third sentences of this
<U>Section</U><U></U><U>&nbsp;11.1.3</U>, the Company (x)&nbsp;shall provide that such action shall apply uniformly to all outstanding Rights, and (y)&nbsp;may suspend the exercisability of the Rights until the expiration of the Substitution Period
in order to seek any authorization of additional shares and/or to decide the appropriate form of distribution to be made pursuant to such first sentence and to determine the value thereof. In the event of any such suspension, the Company shall issue
a public announcement stating that the exercisability of the Rights has been temporarily suspended as well as a public announcement at such time as the suspension is no longer in effect. For purposes of this <U>Section</U><U></U><U>&nbsp;11.1.3</U>,
the value of a share of Common Stock shall be the then current per share market price (as determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) on the date of the occurrence of a Trigger Event and the value of any &#147;common stock
equivalent&#148; shall be deemed to have the same value as the Common Stock on such date. The Board may, but shall not be required to, establish procedures to allocate the right to receive Common Stock upon the exercise of the Rights among holders
of Rights pursuant to this <U>Section</U><U></U><U>&nbsp;11.1.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2. <U>Dilutive Rights Offering</U>. In case the Company shall fix a record date for the
issuance of rights, options or warrants to all holders of Series A Preferred entitling them (for a period expiring within forty-five (45)&nbsp;calendar days after such record date) to subscribe for or purchase Series A Preferred (or securities
having the same rights, privileges and preferences as the Series A Preferred (&#147;<I>equivalent preferred stock</I>&#148;)) or securities convertible into Series A Preferred or equivalent preferred stock at a price per share of Series A Preferred
or per share of equivalent preferred stock (or having a conversion or exercise price per share, if a security convertible into or exercisable for Series A Preferred or equivalent preferred stock) less than the then current per share market price of
the Series A Preferred (as determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) on such record date, the Purchase Price to be in effect after such record date shall be determined by multiplying the Purchase Price in effect immediately
prior to such record date by a fraction, the numerator of which shall be the number of shares of Series A Preferred and shares of equivalent preferred stock outstanding on such record date plus the number of shares of Series A Preferred and shares
of equivalent preferred stock which the aggregate offering price of the total number of shares of Series A Preferred and/or shares of equivalent preferred stock to be offered (and/or the aggregate initial conversion price of the convertible
securities so to be offered) would purchase at such current per share market price and the denominator of which shall be the number of shares of Series A Preferred and shares of equivalent preferred stock outstanding on such record date plus the
number of additional Series A Preferred and/or shares of equivalent preferred stock to be offered for subscription or purchase (or into which the convertible securities so to be offered are initially convertible); <I>provided, however,</I> that in
no event shall the consideration to be paid upon the exercise of one Right be less than the aggregate par value of the shares of capital stock of the Company issuable upon exercise of one Right. In case such subscription price may be paid in a
consideration part or all of which shall be in a form other than cash, the value of such consideration shall be as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent and shall be
binding on the Rights Agent and the holders of the Rights. Series A Preferred and shares of equivalent preferred stock owned by or held for the account of the Company or any Subsidiary of the Company shall not be deemed outstanding for the purpose
of any such computation. Such adjustments shall be made successively whenever such a record date is fixed; and in the event that such rights or warrants are not so issued, the Purchase Price shall be adjusted to be the Purchase Price which would
then be in effect if such record date had not been fixed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3. <U>Distributions</U>. In case the Company shall fix a record date for the
making of a distribution to all holders of the Series A Preferred (including any such distribution made in connection with a consolidation or merger in which the Company is the continuing or surviving corporation) of evidences of indebtedness, cash,
securities or assets (other than a regular periodic cash dividend at a rate not in excess of 125% of the rate of the last regular periodic cash dividend theretofore paid or, in case regular periodic cash dividends have not theretofore been paid, at
a rate not in excess of 50% of the average net income per share of the Company for the four quarters ended immediately prior to the payment of such dividend, or a dividend payable in Series A Preferred (which dividend, for purposes of this
Agreement, shall be subject to the provisions of <U>Section</U><U></U><U>&nbsp;11.1.1(A)</U>)) or convertible securities, or subscription rights or warrants (excluding those referred to in <U>Section</U><U></U><U>&nbsp;11.2</U>), the Purchase Price
to be in effect after such record date shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined by multiplying the Purchase Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the then current per share market price of the Series A
Preferred (as determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) on such record date, less the fair market value (as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent
and shall be binding on the Rights Agent) of the portion of the cash, assets, securities or evidences of indebtedness so to be distributed or of such subscription rights or warrants applicable to one share of Series A Preferred and the denominator
of which shall be such current per share market price of the Series A Preferred (as determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>); <I>provided, however,</I> that in no event shall the consideration to be paid upon the exercise of
one Right be less than the aggregate par value of the shares of capital stock of the Company to be issued upon exercise of one Right. Such adjustments shall be made successively whenever such a record date is fixed; and in the event that such
distribution is not so made, the Purchase Price shall again be adjusted to be the Purchase Price that would then be in effect if such record date had not been fixed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.4. <U>Current Per Share Market Value</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.4.1. <U>General</U>. For the purpose of any computation hereunder, the &#147;<I>current per share market price</I>&#148; of any security
(a &#147;<I>Security</I>&#148; for the purpose of this <U>Section</U><U></U><U>&nbsp;11.4.1</U>) on any date shall be deemed to be the average of the daily closing prices per share of such Security for the thirty (30)&nbsp;consecutive Trading Days
(as such term is hereinafter defined) immediately prior to, but not including, such date; <I>provided, however,</I> that in the event that the then current per share market price of the Security is determined during any period following the
announcement by the issuer of such Security of (i)&nbsp;a dividend or distribution on such Security payable in shares of such Security or securities convertible into such shares or (ii)&nbsp;any subdivision, combination or reclassification of such
Security, and prior to the expiration of thirty (30)&nbsp;Trading Days after the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date for such dividend or distribution, or the record date for such subdivision, combination or reclassification,
then, and in each such case, the &#147;current per share market price&#148; shall be appropriately adjusted to reflect the then current market price per share equivalent of such Security. The closing price for each day shall be the last sale price,
regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or
admitted to trading on the NASDAQ<B> </B>or, if the Security is not listed or admitted to trading on the NASDAQ, as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national
securities exchange on which the Security is listed or admitted to trading or, if the Security is not listed or admitted to trading on any national securities exchange, the last quoted price or, if on such date the Security is not so quoted, the
average of the high bid and low asked prices in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, as reported thereby or such other system then in use, or, if on any such date the Security
is not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the Security selected by the Board. If on any such date no such market maker is making a market in
the Security, the fair value of the Security on such date as determined in good faith by the Board shall be used. The term &#147;<I>Trading Day</I>&#148; shall mean a day on which the principal national securities exchange on which the Security is
listed or admitted to trading is open for the transaction of business or, if the Security is not listed or admitted to trading on any national securities exchange, a Business Day. If the Security is not publicly held or not so listed or traded, or
if on any such date the Security is not so quoted and no such market maker is making a market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Security, &#147;current per share market price&#148; shall mean the fair value per share as determined in good faith by the Board or, if at the time of such determination there is an
Acquiring Person, by a nationally recognized investment banking firm selected by the Board, which shall have the duty to make such determination in a reasonable and objective manner, whose determination shall be described in a statement filed with
the Rights Agent and shall be conclusive for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.4.2. <U>Series A Preferred</U>. Notwithstanding
<U>Section</U><U></U><U>&nbsp;11.4.1</U>, for the purpose of any computation hereunder, the &#147;current per share market price&#148; of the Series A Preferred shall be determined in the same manner as set forth above in
<U>Section</U><U></U><U>&nbsp;11.4.1</U> (other than the last sentence thereof). If the current per share market price of the Series A Preferred cannot be determined in the manner described in <U>Section</U><U></U><U>&nbsp;11.4.1</U>, the
&#147;current per share market price&#148; of the Series A Preferred shall be conclusively deemed to be an amount equal to 1,000 (as such number may be appropriately adjusted for such events as stock splits, stock dividends and recapitalizations
with respect to the Common Stock occurring after the date of this Agreement) multiplied by the current per share market price of the Common Stock (as determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4.1</U>). If neither the Common Stock nor
the Series A Preferred are publicly held or so listed or traded, or if on any such date neither the Common Stock nor the Series A Preferred are so quoted and no such market maker is making a market in either the Common Stock or the Series A
Preferred, &#147;current per share market price&#148; of the Series A Preferred shall mean the fair value per share as determined in good faith by the Board, or, if at the time of such determination there is an Acquiring Person, by a nationally
recognized investment banking firm selected by the Board, which shall have the duty to make such determination in a reasonable and objective manner, which determination shall be described in a statement filed with the Rights Agent and shall be
conclusive for all purposes. For purposes of this Agreement, the &#147;current per share market price&#148; of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred shall be equal to the &#147;current per share
market price&#148; of one share of Series A Preferred divided by 1,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.5. <U>Insignificant Changes</U>. No adjustment in the Purchase
Price shall be required unless such adjustment would require an increase or decrease of at least 1% in the Purchase Price. Any adjustments which by reason of this <U>Section</U><U></U><U>&nbsp;11.5</U> are not required to be made shall be carried
forward and taken into account in any subsequent adjustment. All calculations under this <U>Section</U><U></U><U>&nbsp;11</U> shall be made to the nearest cent or to the nearest <FONT STYLE="white-space:nowrap">one-hundred</FONT> thousandth of a
share of Series A Preferred or the nearest <FONT STYLE="white-space:nowrap">ten-thousandth</FONT> of a share of Common Stock or other share or security, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.6. <U>Shares Other Than Series A Preferred</U>. If as a result of an adjustment made pursuant to <U>Section</U><U></U><U>&nbsp;11.1</U>,
the holder of any Right thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than Series A Preferred, thereafter the number of such other shares so receivable upon exercise of any Right shall be
subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Series A Preferred contained in <U>Sections 11.1, 11.2, 11.3, 11.5, 11.8, 11.9</U> and <U>11.13</U>, and the
provisions of <U>Sections 7, 9, 10, 13</U> and <U>14</U> with respect to the Series A Preferred shall apply on like terms to any such other shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.7. <U>Rights Issued Subsequent to Adjustment</U>. All Rights originally issued by the
Company subsequent to any adjustment made to the Purchase Price hereunder shall evidence the right to purchase, at the adjusted Purchase Price, the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred
and shares of other capital stock or other securities, assets or cash of the Company, if any, purchasable from time to time hereunder upon exercise of the Rights, all subject to further adjustment as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.8. <U>Effect of Adjustments on Existing Rights</U>. Unless the Company shall have exercised its election as provided in
<U>Section</U><U></U><U>&nbsp;11.9</U>, upon each adjustment of the Purchase Price as a result of the calculations made in <U>Sections 11.2</U> and <U>11.3</U>, each Right outstanding immediately prior to the making of such adjustment shall
thereafter evidence the right to purchase, at the adjusted Purchase Price, that number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred (calculated to the nearest
<FONT STYLE="white-space:nowrap">one-hundred</FONT> thousandth of a share of Series A Preferred) obtained by (i)&nbsp;multiplying (x) the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred covered by a
Right immediately prior to this adjustment by (y)&nbsp;the Purchase Price in effect immediately prior to such adjustment of the Purchase Price and (ii)&nbsp;dividing the product so obtained by the Purchase Price in effect immediately after such
adjustment of the Purchase Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.9. <U>Adjustment in Number of Rights</U>. The Company may elect on or after the date of any
adjustment of the Purchase Price to adjust the number of Rights, in substitution for any adjustment in the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred issuable upon the exercise of a Right. Each
of the Rights outstanding after such adjustment of the number of Rights shall be exercisable for the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred for which a Right was exercisable immediately
prior to such adjustment. Each Right held of record prior to such adjustment of the number of Rights shall become that number of Rights (calculated to the nearest <FONT STYLE="white-space:nowrap">ten-thousandth)</FONT> obtained by dividing the
Purchase Price in effect immediately prior to adjustment of the Purchase Price by the Purchase Price in effect immediately after adjustment of the Purchase Price. The Company shall make a public announcement of its election to adjust the number of
Rights, indicating the record date for the adjustment, and, if known at the time, the amount of the adjustment to be made. This record date may be the date on which the Purchase Price is adjusted or any day thereafter, but, if the Right Certificates
have been issued, shall be at least ten (10)&nbsp;days later than the date of the public announcement. If Right Certificates have been issued, upon each adjustment of the number of Rights pursuant to this <U>Section</U><U></U><U>&nbsp;11.9</U>, the
Company may, as promptly as practicable, cause to be distributed to holders of record of Right Certificates on such record date Right Certificates evidencing, subject to <U>Section</U><U></U><U>&nbsp;14</U>, the additional Rights to which such
holders shall be entitled as a result of such adjustment, or, at the option of the Company, shall cause to be distributed to such holders of record in substitution and replacement for the Right Certificates held by such holders prior to the date of
adjustment, and upon surrender thereof, if required by the Company, new Right Certificates evidencing all the Rights to which such holders shall be entitled after such adjustment. Right Certificates so to be distributed shall be issued, executed and
countersigned in the manner provided for herein (and may bear, at the option of the Company, the adjusted Purchase Price) and shall be registered in the names of the holders of record of Right Certificates on the record date specified in the public
announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.10. <U>Right Certificates Unchanged</U>. Irrespective of any adjustment or change in the Purchase Price or the number of
<FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred issuable upon the exercise of the Rights, the Right Certificates theretofore and thereafter issued may continue to express the Purchase Price per share and the
number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred which were expressed in the initial Right Certificates issued hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.11. <U>Par Value Limitations</U>. Before taking any action that would cause an adjustment
reducing the Purchase Price below one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of the then par value, if any, of the Series A Preferred or other shares of capital stock issuable upon exercise of the Rights, the Company shall take any
corporate action which may, in the opinion of its counsel, be necessary in order that the Company may validly and legally issue fully paid and nonassessable Series A Preferred or other such shares at such adjusted Purchase Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.12. <U>Deferred Issuance</U>. In any case in which this <U>Section</U><U></U><U>&nbsp;11</U> shall require that an adjustment in the
Purchase Price be made effective as of a record date for a specified event, the Company may elect to defer until the occurrence of such event the issuance to the holder of any Right exercised after such record date of that number of shares of Series
A Preferred and shares of other capital stock or securities of the Company, if any, issuable upon such exercise over and above the Series A Preferred and shares of other capital stock or other securities, assets or cash of the Company, if any,
issuable upon such exercise on the basis of the Purchase Price in effect prior to such adjustment; <I>provided, however,</I> that the Company shall deliver to such holder a due bill or other appropriate instrument evidencing such holder&#146;s right
to receive such additional shares upon the occurrence of the event requiring such adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.13. <U>Reduction in Purchase Price</U>.
Anything in this <U>Section</U><U></U><U>&nbsp;11</U> to the contrary notwithstanding, the Company shall be entitled to make such reductions in the Purchase Price, in addition to those adjustments expressly required by this
<U>Section</U><U></U><U>&nbsp;11</U>, as and to the extent that it in its sole discretion shall determine to be advisable in order that any consolidation or subdivision of the Series A Preferred, issuance wholly for cash of any of the Series A
Preferred at less than the current market price, issuance wholly for cash of Series A Preferred or securities which by their terms are convertible into or exchangeable for Series A Preferred, dividends on Series A Preferred payable in Series A
Preferred or issuance of rights, options or warrants referred to hereinabove in this <U>Section</U><U></U><U>&nbsp;11</U>, hereafter made by the Company to holders of its Series A Preferred shall not be taxable to such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.14. <U>Company Not to Diminish Benefits of Rights</U>. The Company covenants and agrees that after the earlier of the Stock Acquisition
Date or Distribution Date it will not, except as permitted by <U>Section</U><U></U><U>&nbsp;23</U>, <U>Section</U><U></U><U>&nbsp;26</U> or <U>Section</U><U></U><U>&nbsp;27</U>, take (or permit any Subsidiary to take) any action if at the time such
action is taken it is reasonably foreseeable that such action will substantially diminish or otherwise eliminate the benefits intended to be afforded by the Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.15. <U>Adjustment of Rights Associated with Common Stock</U>. Notwithstanding anything contained in this Agreement to the contrary, in the
event that the Company shall at any time after the date hereof and prior to the Distribution Date (i)&nbsp;declare or pay any dividend on the outstanding Common Stock payable in shares of Common Stock, (ii)&nbsp;effect a subdivision or consolidation
of the outstanding Common Stock (by reclassification or otherwise than by the payment of dividends payable in shares of Common Stock), or (iii)&nbsp;combine the outstanding Common Stock into a greater or lesser number of shares of Common Stock, then
in any such case, the number of Rights associated with each share of Common Stock then outstanding, or issued or delivered thereafter but prior to the Distribution Date or in accordance with <U>Section</U><U></U><U>&nbsp;22</U> shall be
proportionately adjusted so that the number of Rights thereafter associated with each share of Common Stock following any such event shall equal the result obtained by multiplying the number of Rights associated with each share of Common Stock
immediately prior to such event by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fraction, the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to the occurrence of the event and the denominator of which shall be the total
number of shares of Common Stock outstanding immediately following the occurrence of such event. The adjustments provided for in this <U>Section</U><U></U><U>&nbsp;11.15</U> shall be made successively whenever such a dividend is declared or paid or
such a subdivision, combination or consolidation is effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Certificate of Adjusted Purchase Price or Number of
Shares</U>. Whenever an adjustment is made as provided in <U>Sections 11</U> or <U>13</U>, the Company shall (a)&nbsp;promptly prepare a certificate setting forth such adjustment, and a brief statement of the facts accounting for such adjustment,
(b)&nbsp;promptly file with the Rights Agent and with each transfer agent for the Common Stock or the Series A Preferred a copy of such certificate and (c)&nbsp;mail a brief summary thereof to each holder of a Right Certificate (or if before the
Distribution Date, to each holder of a certificate representing shares of Common Stock or Book Entry Shares in respect thereof) in accordance with <U>Section</U><U></U><U>&nbsp;25</U>. The Rights Agent shall be fully protected in relying on any such
certificate and on any adjustment or statement therein contained and shall not be deemed to have knowledge of any such adjustment unless and until it shall have received such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U>Consolidation, Merger or Sale or Transfer of Assets or Earning Power</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1. <U>Certain Transactions</U>. In the event that, from and after the first occurrence of a Trigger Event, directly or indirectly,
(A)&nbsp;the Company shall consolidate with, or merge with and into, any other Person and the Company shall not be the continuing or surviving corporation, (B)&nbsp;any Person shall consolidate with the Company, or merge with and into the Company
and the Company shall be the continuing or surviving corporation of such merger and, in connection with such merger, all or part of the Common Stock shall be changed into or exchanged for stock or other securities of the Company or any other Person
or cash or any other property, or (C)&nbsp;the Company shall sell, exchange, mortgage or otherwise transfer (or one or more of its Subsidiaries shall sell, exchange, mortgage or otherwise transfer), in one or more transactions, assets or earning
power aggregating 50% or more of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to any other Person or Persons (other than the Company or one or more wholly-owned Subsidiaries of the Company in one or more
transactions each of which complies with <U>Section</U><U></U><U>&nbsp;11.14</U>), then, and in each such case, proper provision shall be made so that (i)&nbsp;each holder of a Right (other than Rights which have become void pursuant to
<U>Section</U><U></U><U>&nbsp;11.1.2</U>) shall thereafter have the right to receive, upon the exercise thereof at a price per Right equal to the then current Purchase Price multiplied by the number of
<FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred for which a Right was exercisable immediately prior to the first occurrence of a Trigger Event (as subsequently adjusted pursuant to <U>Sections 11.1.1</U>,
<U>11.2</U>, <U>11.3</U>, <U>11.8</U>, <U>11.9</U> and <U>11.12</U>), in accordance with the terms of this Agreement and in lieu of Series A Preferred or Common Stock, such number of validly authorized and issued, fully paid, <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and freely tradable Common Stock of the Principal Party (as such term is hereinafter defined) not subject to any liens, encumbrances, rights of first refusal or other adverse claims, as shall be equal
to the result obtained by (x)&nbsp;multiplying the then current Purchase Price by the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred for which a Right was exercisable immediately prior to the first
occurrence of a Trigger Event (as subsequently adjusted pursuant to <U>Sections 11.1.1</U>, <U>11.2</U>, <U>11.3</U>, <U>11.8</U>, <U>11.9</U> and <U>11.12</U>) and (y) dividing that product by 50% of the then current per share market price of the
Common Stock of such Principal Party (determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) on the date of consummation of such consolidation, merger, sale or transfer; <I>provided</I> that the price per Right so payable and the number
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of shares of Common Stock of such Principal Party so receivable upon exercise of a Right shall thereafter be subject to further adjustment as appropriate in accordance with
<U>Section</U><U></U><U>&nbsp;11.6</U> to reflect any events covered thereby occurring in respect of the Common Stock of such Principal Party after the occurrence of such consolidation, merger, sale or transfer; (ii)&nbsp;such Principal Party shall
thereafter be liable for, and shall assume, by virtue of such consolidation, merger, sale or transfer, all of the obligations and duties of the Company pursuant to this Agreement; (iii)&nbsp;the term &#147;Company&#148; shall thereafter be deemed to
refer to such Principal Party; and (iv)&nbsp;such Principal Party shall take such steps (including, but not limited to, the reservation of a sufficient number of shares of its Common Stock in accordance with <U>Section</U><U></U><U>&nbsp;9</U>) in
connection with such consummation as may be necessary to assure that the provisions hereof shall thereafter be applicable, as nearly as reasonably may be, in relation to its Common Stock thereafter deliverable upon the exercise of the Rights;
<I>provided</I> that, upon the subsequent occurrence of any consolidation, merger, sale or transfer of assets or other extraordinary transaction in respect of such Principal Party, each holder of a Right shall thereupon be entitled to receive, upon
exercise of a Right and payment of the Purchase Price as provided in this <U>Section</U><U></U><U>&nbsp;13.1</U>, such cash, shares, rights, warrants and other property which such holder would have been entitled to receive had such holder, at the
time of such transaction, owned the Common Stock of the Principal Party receivable upon the exercise of a Right pursuant to this <U>Section</U><U></U><U>&nbsp;13.1</U>, and such Principal Party shall take such steps (including, but not limited to,
reservation of shares of stock) as may be necessary to permit the subsequent exercise of the Rights in accordance with the terms hereof for such cash, shares, rights, warrants and other property. The Company shall not consummate any such
consolidation, merger, sale or transfer unless prior thereto the Company and such Principal Party shall have executed and delivered to the Rights Agent a supplemental agreement confirming that the requirements of this
<U>Section</U><U></U><U>&nbsp;13.1</U> and <U>Section</U><U></U><U>&nbsp;13.2</U> shall promptly be performed in accordance with their terms and that such consolidation, merger, sale or transfer of assets shall not result in a default by the
Principal Party under this Agreement as the same shall have been assumed by the Principal Party pursuant to this <U>Section</U><U></U><U>&nbsp;13.1</U> and <U>Section</U><U></U><U>&nbsp;13.2</U> and providing that, as soon as practicable after
executing such agreement pursuant to this <U>Section</U><U></U><U>&nbsp;13</U>, the Principal Party, at its own expense, shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1)
prepare and file a registration statement under the Securities Act, if necessary, with respect to the Rights and the securities purchasable upon exercise of the Rights on an appropriate form, use its best efforts to cause such registration statement
to become effective as soon as practicable after such filing and use its best efforts to cause such registration statement to remain effective (with a prospectus at all times meeting the requirements of the Securities Act) until the Expiration Date
and similarly comply with applicable state securities laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) use its best efforts, if the Common Stock of the Principal Party shall be
listed or admitted to trading on the NASDAQ&nbsp;or on another national securities exchange, to list or admit to trading (or continue the listing of) the Rights and the securities purchasable upon exercise of the Rights on the NASDAQ<B></B>&nbsp;or
such securities exchange; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) deliver to holders of the Rights historical financial statements for the Principal Party which comply in
all respects with the requirements for registration on Form 10 (or any successor form) under the Exchange Act; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) obtain waivers of any rights of first refusal or preemptive rights in respect of the
Common Stock of the Principal Party subject to purchase upon exercise of outstanding Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In case the Principal Party has a provision
in any of its authorized securities or in its articles or certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> or other instrument governing its corporate affairs, which provision would have the effect of (i)&nbsp;causing
such Principal Party to issue (other than to holders of Rights pursuant to this <U>Section</U><U></U><U>&nbsp;13</U>), in connection with, or as a consequence of, the consummation of a transaction referred to in this
<U>Section</U><U></U><U>&nbsp;13</U>, Common Stock or common stock equivalents of such Principal Party at less than the then current market price per share thereof (determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) or securities
exercisable for, or convertible into, Common Stock or common stock equivalents of such Principal Party at less than such then current market price (other than to holders of Rights pursuant to this <U>Section</U><U></U><U>&nbsp;13</U>), or
(ii)&nbsp;providing for any special payment, taxes, charges or similar provision in connection with the issuance of the Common Stock of such Principal Party pursuant to the provision of <U>Section</U><U></U><U>&nbsp;13</U>, then, in such event, the
Company hereby agrees with each holder of Rights that it shall not consummate any such transaction unless prior thereto the Company and such Principal Party shall have executed and delivered to the Rights Agent a supplemental agreement providing
that the provision in question of such Principal Party shall have been canceled, waived or amended, or that the authorized securities shall be redeemed, so that the applicable provision will have no effect in connection with, or as a consequence of,
the consummation of the proposed transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees that it shall not, at any time after the Trigger Event,
enter into any transaction of the type described in clauses (A)&nbsp;through (C) of this <U>Section</U><U></U><U>&nbsp;13.1</U> if (i)&nbsp;at the time of or immediately after such consolidation, merger, sale, transfer or other transaction there are
any rights, warrants or other instruments or securities outstanding or agreements in effect which would substantially diminish or otherwise eliminate the benefits intended to be afforded by the Rights, (ii)&nbsp;prior to, simultaneously with or
immediately after such consolidation, merger, sale, transfer or other transaction, the stockholders of the Person who constitutes, or would constitute, the Principal Party for purposes of <U>Section</U><U></U><U>&nbsp;13.2</U> shall have received a
distribution of Rights previously owned by such Person or any of its Related Persons or (iii)&nbsp;the form or nature of organization of the Principal Party would preclude or limit the exercisability of the Rights. The provisions of this
<U>Section</U><U></U><U>&nbsp;13</U> shall similarly apply to successive transactions of the type described in clauses (A)&nbsp;through (C) of this <U>Section</U><U></U><U>&nbsp;13.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2. <U>Principal Party</U>. &#147;<I>Principal Party</I>&#148; shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) in the case of any transaction described in clauses (A)&nbsp;or (B) of the first sentence of <U>Section</U><U></U><U>&nbsp;13.1</U>: (i)
the Person that is the issuer of the securities into which the Common Stock is converted in such merger or consolidation, or, if there is more than one such issuer, the issuer the Common Stock of which has the greatest aggregate market value of
shares outstanding, or (ii)&nbsp;if no securities are so issued, (x)&nbsp;the Person that is the other party to the merger, if such Person survives said merger, or, if there is more than one such Person, the Person the Common Stock of which has the
greatest aggregate market value of shares outstanding or (y)&nbsp;if the Person that is the other party to the merger does not survive the merger, the Person that does survive the merger (including the Company if it survives) or (z)&nbsp;the Person
resulting from the consolidation; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) in the case of any transaction described in clause (C)&nbsp;of the first sentence in
<U>Section</U><U></U><U>&nbsp;13.1</U>, the Person that is the party receiving the greatest portion of the assets or earning power transferred pursuant to such transaction or transactions, or, if each Person that is a party to such transaction or
transactions receives the same portion of the assets or earning power so transferred or if the Person receiving the greatest portion of the assets or earning power cannot be determined, whichever of such Persons is the issuer of Common Stock having
the greatest aggregate market value of shares outstanding; <I>provided, however,</I> that in any such case described in the foregoing clause (i)&nbsp;or (ii) of this <U>Section</U><U></U><U>&nbsp;13.2</U>, if the shares of Common Stock of such
Person are not at such time or have not been continuously over the preceding twelve (12)&nbsp;month period registered under Section&nbsp;12 of the Exchange Act, then (1)&nbsp;if such Person is a direct or indirect Subsidiary of another Person the
shares of Common Stock of which are and have been so registered, the term &#147;Principal Party&#148; shall refer to such other Person, or (2)&nbsp;if such Person is a Subsidiary, directly or indirectly, of more than one Person, the shares of Common
Stock of all of which are and have been so registered, the term &#147;Principal Party&#148; shall refer to whichever of such Persons is the issuer of Common Stock having the greatest aggregate market value of shares outstanding, or (3)&nbsp;if such
Person is owned, directly or indirectly, by a joint venture formed by two or more Persons that are not owned, directly or indirectly, by the same Person, the rules set forth in clauses (1)&nbsp;and (2) above shall apply to each of the owners having
an interest in the venture as if the Person owned by the joint venture was a Subsidiary of both or all of such joint venturers, and the Principal Party in each such case shall bear the obligations set forth in this
<U>Section</U><U></U><U>&nbsp;13</U> in the same ratio as its interest in such Person bears to the total of such interests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.3.
<U>Approved Acquisitions</U>. Notwithstanding anything contained herein to the contrary, upon the consummation of any merger or other acquisition transaction of the type described in clause (A), (B) or (C)&nbsp;of
<U>Section</U><U></U><U>&nbsp;13.1</U> involving the Company pursuant to a merger or other acquisition agreement between the Company and any Person (or one or more of such Person&#146;s Affiliates or Associates) which agreement has been approved by
the Board prior to any Person becoming an Acquiring Person, this Agreement and the rights of holders of Rights hereunder shall be terminated in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Fractional Rights and Fractional Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.1. <U>Cash in Lieu of Fractional Rights</U>. The Company shall not be required to issue fractions of Rights or to distribute Right
Certificates which evidence fractional Rights (except prior to the Distribution Date in accordance with <U>Section</U><U></U><U>&nbsp;11.15</U>). In lieu of such fractional Rights, there shall be paid to the registered holders of the Right
Certificates with regard to which such fractional Rights would otherwise be issuable an amount in cash equal to the same fraction of the current market value of a whole Right. For the purposes of this <U>Section</U><U></U><U>&nbsp;14.1</U>, the
current market value of a whole Right shall be the closing price of the Rights for the Trading Day immediately prior to the date on which such fractional Rights would have been otherwise issuable. The closing price for any day shall be the last sale
price, regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities
listed or admitted to trading on the NASDAQ or, if the Rights are not listed or admitted to trading on the NASDAQ, as reported in the principal consolidated transaction reporting system with respect to securities listed on the principal national
securities exchange on which the Rights are listed or admitted to trading or, if the Rights are not listed or admitted to trading on any national securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange, the last quoted price or, if not so quoted, the average of the high bid and low asked prices in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, as reported by the NASDAQ or such other system then in use or, if on any such date the Rights are not quoted by any such organization, the
average of the closing bid and asked prices as furnished by a professional market maker making a market in the Rights selected by the Board. If on any such date no such market maker is making a market in the Rights, the current market value of the
Rights on such date shall be the fair value of the Rights as determined in good faith by the Board, or, if at the time of such determination there is an Acquiring Person, by a nationally recognized investment banking firm selected by the Board,
which shall have the duty to make such determination in a reasonable and objective manner, which determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.2. <U>Cash in Lieu of Fractional Shares of Series A Preferred</U>. The Company shall not be required to issue fractions of shares of Series
A Preferred (other than fractions which are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred) upon exercise or exchange of the Rights or to distribute certificates which evidence
fractional shares of Series A Preferred (other than fractions which are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred). Interests in fractions of shares of Series A Preferred in
integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred may, at the election of the Company, be evidenced by depositary receipts, pursuant to an appropriate agreement between the Company and
a depositary selected by it; <I>provided,</I> that such agreement shall provide that the holders of such depositary receipts shall have all the rights, privileges and preferences to which they are entitled as Beneficial Owners of the Series A
Preferred represented by such depositary receipts. In lieu of fractional shares of Series A Preferred that are not integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred, the Company shall
pay to the registered holders of Right Certificates at the time such Rights are exercised or exchanged as herein provided an amount in cash equal to the same fraction of the current per share market price of one share of Series A Preferred (as
determined in accordance with <U>Section</U><U></U><U>&nbsp;14.1</U>) for the Trading Day immediately prior to the date of such exercise or exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3. <U>Cash in Lieu of Fractional Shares of Common Stock</U>. The Company shall not be required to issue fractions of shares of Common Stock
or to distribute certificates which evidence fractional shares of Common Stock upon the exercise or exchange of Rights. In lieu of such fractional shares of Common Stock, the Company shall pay to the registered holders of the Right Certificates with
regard to which such fractional shares of Common Stock would otherwise be issuable an amount in cash equal to the same fraction of the current market value of a whole share of Common Stock (as determined in accordance with
<U>Section</U><U></U><U>&nbsp;14.1</U>) for the Trading Day immediately prior to the date of such exercise or exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.4. <U>Waiver of
Right to Receive Fractional Rights or Shares</U>. The holder of a Right by the acceptance of the Rights expressly waives his right to receive any fractional Rights or any fractional shares upon exercise or exchange of a Right, except as permitted by
this <U>Section</U><U></U><U>&nbsp;14</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Rights of Action</U>. All rights of action in respect of this Agreement,
except the rights of action given to the Rights Agent under <U>Section</U><U></U><U>&nbsp;18</U>, are vested in the respective registered holders of the Right Certificates (and, prior to the Distribution Date, the registered holders of the Common
Stock); and any registered holder of any Right Certificate (or, prior to the Distribution Date, of the Common Stock), without the consent of the Rights Agent or of the holder of any other Right Certificate (or, prior to the Distribution Date, of the
Common Stock), may, in his own behalf and for his own benefit, enforce this Agreement, and may institute and maintain any suit, action or proceeding against the Company to enforce this Agreement, or otherwise enforce or act in respect of his right
to exercise the Rights evidenced by such Right Certificate (or, prior to the Distribution Date, such Common Stock) in the manner provided in such Right Certificate and in this Agreement. Without limiting the foregoing or any remedies available to
the holders of Rights, it is specifically acknowledged that the holders of Rights would not have an adequate remedy at law for any breach of this Agreement and shall be entitled to specific performance of the obligations under, and injunctive relief
against actual or threatened violations of, the obligations of any Person (including, without limitation, the Company) subject to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Agreement of Right Holders</U>. Every holder of a Right by accepting the same consents and agrees with the Company and the
Rights Agent and with every other holder of a Right that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) prior to the Distribution Date, the Rights will not be
evidenced by a Right Certificate and will be transferable only in connection with the transfer of the Common Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) as
of and after the Distribution Date, the Right Certificates are transferable only on the registry books of the Rights Agent if surrendered at the office of the Rights Agent designated for such purpose, duly endorsed or accompanied by a proper
instrument of transfer with all required certifications completed; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the Company and the Rights Agent may deem and
treat the Person in whose name the Right Certificate (or, prior to the Distribution Date, the associated Common Stock certificate or Book Entry Share) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding
any notations of ownership or writing on the Right Certificates or the associated Common Stock certificate or Book Entry Share made by anyone other than the Company or the Rights Agent) for all purposes whatsoever, and neither the Company nor the
Rights Agent shall be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Right Certificate Holder Not Deemed a Stockholder</U>.
No holder, as such, of any Right Certificate shall be entitled to vote, receive dividends or be deemed for any purpose the holder of the Series A Preferred or any other securities of the Company which may at any time be issuable on the exercise of
the Rights represented thereby, nor shall anything contained herein or in any Right Certificate be construed to confer upon the holder of any Right Certificate, as such, any of the rights of a stockholder of the Company or any right to vote for the
election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting stockholders (except as provided in
<U>Section</U><U></U><U>&nbsp;24</U>), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by such Right Certificate shall have been exercised in accordance with the provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Concerning the Rights Agent</U>. The Company agrees to pay to the Rights
Agent reasonable compensation for all services rendered by it hereunder in accordance with a fee schedule to be mutually agreed upon and, from time to time, on demand of the Rights Agent, its reasonable expenses and counsel fees and other
disbursements incurred in the administration and execution of this Agreement and the exercise and performance of its duties hereunder. The Company also agrees to indemnify the Rights Agent for, and to hold it harmless against, any loss, liability,
or expense, incurred without gross negligence, bad faith or willful misconduct on the part of the Rights Agent, for anything done or omitted by the Rights Agent in connection with the acceptance and administration of this Agreement, including the
costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Rights Agent shall be
protected and shall incur no liability for or in respect of any action taken, suffered or omitted by it in connection with its administration of this Agreement in reliance upon any Right Certificate or certificate for the Series A Preferred or the
Common Stock or for other securities of the Company, instrument of assignment or transfer, power of attorney, endorsement, affidavit, letter, notice, instruction, direction, consent, certificate, statement, or other paper or document believed by it
to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Merger or Consolidation or Change of Name of Rights Agent</U>. Any corporation or limited liability company or other
entity into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any corporation or limited liability company or other entity resulting from any merger or consolidation to which the Rights Agent
or any successor Rights Agent shall be a party, or any corporation or limited liability company succeeding to the corporate trust or stock transfer business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights
Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, <I>provided</I> that such corporation or limited liability company or other entity would be eligible for appointment
as a successor Rights Agent under the provisions of <U>Section</U><U></U><U>&nbsp;21</U>. In case at the time such successor Rights Agent shall succeed to the agency created by this Agreement, any of the Right Certificates shall have been
countersigned but not delivered, any such successor Rights Agent may adopt the countersignature of the predecessor Rights Agent and deliver such Right Certificates so countersigned; and in case at that time any of the Right Certificates shall not
have been countersigned, any successor Rights Agent may countersign such Right Certificates either in the name of the predecessor Rights Agent or in the name of the successor Rights Agent; and in all such cases such Right Certificates shall have the
full force provided in the Right Certificates and in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In case at any time the name of the Rights Agent shall be changed
and at such time any of the Right Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Right Certificates so countersigned; and in case at that time any of the
Right Certificates shall not have been countersigned, the Rights Agent may countersign such Right Certificates either in its prior name or in its changed name; and in all such cases such Right Certificates shall have the full force provided in the
Right Certificates and in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Duties of Rights Agent</U>. The Rights Agent undertakes the duties and
obligations imposed by this Agreement upon the following terms and conditions, by all of which the Company and the holders of Right Certificates, by their acceptance thereof, shall be bound: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.1. <U>Legal Counsel</U>. The Rights Agent may consult with legal counsel selected by it (who may be legal counsel for the Company), and the
opinion of such counsel shall be full and complete authorization and protection to the Rights Agent as to any action taken or omitted by it in good faith and in accordance with such opinion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.2. <U>Certificates as to Facts or Matters</U>. Whenever in the performance of its duties under this Agreement the Rights Agent shall deem it
necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed
to be conclusively proved and established by a certificate signed by any one of the Chief Executive Officer, the Chief Financial Officer or the Chief Legal Officer of the Company and delivered to the Rights Agent; and such certificate shall be full
authorization to the Rights Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.3. <U>Standard of Care</U>. The Rights Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.4. <U>Reliance on Agreement and Right Certificates</U>. The Rights Agent shall not be liable for or by reason of any of the statements
of fact or recitals contained in this Agreement or in the Right Certificates (except as to its countersignature thereof) or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company
only. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.5. <U>No Responsibility as to Certain Matters</U>. The Rights Agent shall not be under any responsibility in respect of the
validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Rights Agent) or in respect of the validity or execution of any Right Certificate (except its countersignature thereof); nor shall it be
responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Right Certificate; nor shall it be responsible for any change in the exercisability of the Rights (including the Rights becoming void
pursuant to <U>Section</U><U></U><U>&nbsp;11.1.2</U>) or any adjustment required under the provisions of <U>Sections 3, 11, 13, 23</U> or <U>27</U> or responsible for the manner, method or amount of any such adjustment or the ascertaining of the
existence of facts that would require any such adjustment (except with respect to the exercise of Rights evidenced by Right Certificates after actual notice of any such change or adjustment); nor shall it by any act hereunder be deemed to make any
representation or warranty as to the authorization or reservation of any Series A Preferred or other securities to be issued pursuant to this Agreement or any Right Certificate or as to whether any Series A Preferred or other securities will, when
so issued, be validly authorized and issued, fully paid and nonassessable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.6. <U>Further Assurance by Company</U>. The Company agrees
that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out
or performing by the Rights Agent of the provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.7. <U>Authorized Company Officers</U>. The Rights Agent is hereby authorized and directed
to accept instructions with respect to the performance of its duties hereunder from any one of the Chief Executive Officer, the Chief Financial Officer or the Chief Legal Officer of the Company, and to apply to such officers for advice or
instructions in connection with its duties under this Agreement, and it shall not be liable for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer or for any delay in acting while waiting
for these instructions. Any application by the Rights Agent for written instructions from the Company may, at the option of the Rights Agent, set forth in writing any action proposed to be taken or omitted by the Rights Agent with respect to its
duties or obligations under this Agreement and the date on and/or after which such action shall be taken or such omission shall be effective. The Rights Agent shall not be liable to the Company for any action taken by, or omission of, the Rights
Agent in accordance with a proposal included in any such application on or after the date specified therein (which date shall not be less than three (3)&nbsp;Business Days after the date any such officer actually receives such application, unless
any such officer shall have consented in writing to an earlier date) unless, prior to taking of any such action (or the effective date in the case of omission), the Rights Agent shall have received written instructions in response to such
application specifying the action to be taken or omitted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.8. <U>Freedom to Trade in Company Securities</U>. The Rights Agent and any
stockholder, director, officer or employee of the Rights Agent may buy, sell or deal in any of the Rights or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with
or lend money to the Company or otherwise act as fully and freely as though it were not Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Company or for any other legal
entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.9. <U>Reliance on Attorneys and Agents</U>. The Rights Agent may execute and exercise any of the rights or powers hereby vested
in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any
loss to the Company resulting from any such act, omission, default, neglect or misconduct, <I>provided</I> that reasonable care was exercised in the selection and continued employment thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.10. <U>Incomplete Certificate</U>. If, with respect to any Right Certificate surrendered to the Rights Agent for exercise or transfer, the
certificate contained in the form of assignment or the form of election to purchase set forth on the reverse thereof, as the case may be, has not been completed to certify the holder is not an Acquiring Person (or a Related Person of an Acquiring
Person), the Rights Agent shall not take any further action with respect to such requested exercise or transfer without first consulting with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.11. <U>Rights Holders List</U>. At any time and from time to time after the Distribution
Date, upon the request of the Company, the Rights Agent shall promptly deliver to the Company a list, as of the most recent practicable date (or as of such earlier date as may be specified by the Company), of the holders of record of Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Change of Rights Agent</U>. The Rights Agent or any successor Rights Agent may resign and be discharged from its duties
under this Agreement upon thirty (30)&nbsp;days&#146; notice in writing mailed to the Company and to each transfer agent of the Common Stock and/or Series A Preferred, as applicable, by registered or certified mail. Following the Distribution Date,
the Company shall promptly notify the holders of the Right Certificates by first-class mail of any such resignation. The Company may remove the Rights Agent or any successor Rights Agent upon thirty (30)&nbsp;days&#146; notice in writing, mailed to
the Rights Agent or successor Rights Agent, as the case may be, and to each transfer agent of the Common Stock and/or Series A Preferred, as applicable, by registered or certified mail, and to the holders of the Right Certificates by first-class
mail. If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the resigning, removed, or incapacitated Rights Agent shall remit to the Company, or to any successor Rights Agent designated by the Company, all
books, records, funds, certificates or other documents or instruments of any kind then in its possession which were acquired by such resigning, removed or incapacitated Rights Agent in connection with its services as Rights Agent hereunder, and
shall thereafter be discharged from all duties and obligations hereunder. Following notice of such removal, resignation or incapacity, the Company shall appoint a successor to such Rights Agent. If the Company shall fail to make such appointment
within a period of thirty (30)&nbsp;days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of a Right Certificate (who
shall, with such notice, submit his Right Certificate for inspection by the Company), then the registered holder of any Right Certificate may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor
Rights Agent, whether appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the State of New York or the State of Delaware (or any other state of the United States so long as such
corporation is authorized to do business as a banking institution in the State of New York or the State of Delaware) in good standing, having an office in the State of New York or the State of Delaware, which is authorized under such laws to
exercise stock transfer or corporate trust powers and is subject to supervision or examination by Federal or state authority and which has at the time of its appointment as Rights Agent a combined capital and surplus of at least $100&nbsp;million.
After appointment, the successor Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor Rights Agent shall deliver
and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment the
Company shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent of the Common Stock and/or Series A Preferred, as applicable, and, following the Distribution Date, mail a notice thereof in writing to the
registered holders of the Right Certificates. Failure to give any notice provided for in this <U>Section</U><U></U><U>&nbsp;21</U>, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights
Agent or the appointment of the successor Rights Agent, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Issuance of New Right Certificates</U>. Notwithstanding any of the
provisions of this Agreement or of the Rights to the contrary, the Company may, at its option, issue new Right Certificates evidencing Rights in such form as may be approved by its Board to reflect any adjustment or change in the Purchase Price and
the number or kind or class of shares or other securities or property purchasable under the Right Certificates made in accordance with the provisions of this Agreement. In addition, in connection with the issuance or sale of Common Stock following
the Distribution Date and prior to the Expiration Date, the Company shall, with respect to Common Stock so issued or sold pursuant to the exercise of stock options or under any employee plan or arrangement, granted or awarded, or upon exercise,
conversion or exchange of securities heretofore or hereinafter issued by the Company, in each case existing prior to the Distribution Date, issue Right Certificates representing the appropriate number of Rights in connection with such issuance or
sale; <I>provided, however,</I> that (i)&nbsp;no such Right Certificate shall be issued if, and to the extent that, the Company shall be advised by counsel that such issuance would create a significant risk of material adverse tax consequences to
the Company or the Person to whom such Right Certificate would be issued and (ii)&nbsp;no such Right Certificate shall be issued if, and to the extent that, appropriate adjustment shall otherwise have been made in lieu of the issuance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23. <U>Redemption</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">23.1. <U>Right to Redeem</U>. The Board may, at its option, at any time prior to a Trigger Event, redeem all but not less than all of the then
outstanding Rights at a redemption price of $0.01 per Right, appropriately adjusted to reflect any stock split, stock dividend, recapitalization or similar transaction occurring after the date hereof (such redemption price being hereinafter referred
to as the &#147;<I>Redemption Price</I>&#148;), and the Company may, at its option, pay the Redemption Price in Common Stock (based on the &#147;current per share market price,&#148; determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>, of
the Common Stock at the time of redemption), cash or any other form of consideration deemed appropriate by the Board. The redemption of the Rights by the Board may be made effective at such time, on such basis and subject to such conditions as the
Board in its sole discretion may establish. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">23.2. <U>Redemption Procedures</U>. Immediately upon the action of the Board ordering the
redemption of the Rights (or at such later time as the Board may establish for the effectiveness of such redemption), and without any further action and without any notice, the right to exercise the Rights will terminate and the only right
thereafter of the holders of Rights shall be to receive the Redemption Price for each Right so held. The Company shall promptly give public notice of such redemption; <I>provided, however,</I> that the failure to give, or any defect in, any such
notice shall not affect the validity of such redemption. The Company shall promptly give, or cause the Rights Agent to give, notice of such redemption to the holders of the then outstanding Rights by mailing such notice to all such holders at their
last addresses as they appear upon the registry books of the Rights Agent or, prior to the Distribution Date, on the registry books of the transfer agent for the Common Stock. Any notice which is mailed in the manner herein provided shall be deemed
given, whether or not the holder receives the notice. Each such notice of redemption shall state the method by which the payment of the Redemption Price will be made. The failure to give notice required by this <U>Section</U><U></U><U>&nbsp;23.2</U>
or any defect therein shall not affect the validity of the action taken by the Company. Neither the Company nor any of its Affiliates or Associates may redeem, acquire or purchase for value any Rights at any time in any manner other than that
specifically set forth in this <U>Section</U><U></U><U>&nbsp;23</U> or in <U>Section</U><U></U><U>&nbsp;27</U>, and other than in connection with the purchase, acquisition or redemption of Common Stock prior to the Distribution Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Notice of Certain Events</U>. In case the Company shall propose at any
time after the earlier of the Stock Acquisition Date and the Distribution Date (a)&nbsp;to pay any dividend payable in stock of any class to the holders of Series A Preferred or to make any other distribution to the holders of Series A Preferred
(other than a regular periodic cash dividend at a rate not in excess of 125% of the rate of the last regular periodic cash dividend theretofore paid or, in case regular periodic cash dividends have not theretofore been paid, at a rate not in excess
of 50% of the average net income per share of the Company for the four quarters ended immediately prior to the payment of such dividends, or a stock dividend on, or a subdivision, combination or reclassification of the Common Stock), or (b)&nbsp;to
offer to the holders of Series A Preferred rights or warrants to subscribe for or to purchase any additional Series A Preferred or shares of stock of any class or any other securities, rights or options, or (c)&nbsp;to effect any reclassification of
its Series A Preferred (other than a reclassification involving only the subdivision of outstanding Series A Preferred), or (d)&nbsp;to effect any consolidation or merger into or with, or to effect any sale or other transfer (or to permit one or
more of its Subsidiaries to effect any sale or other transfer), in one or more transactions, of 50% or more of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to, any other Person (other than pursuant to a merger
or other acquisition agreement of the type excluded from the definition of &#147;Beneficial Ownership&#148; in <U>Section</U><U></U><U>&nbsp;1.3</U>), or (e)&nbsp;to effect the liquidation, dissolution or winding up of the Company, or (f)&nbsp;to
declare or pay any dividend on the Common Stock payable in Common Stock or to effect a subdivision, combination or consolidation of the Common Stock (by reclassification or otherwise than by payment of dividends in Common Stock), then, in each such
case, the Company shall give to the Rights Agent and to each holder of a Right Certificate, in accordance with <U>Section</U><U></U><U>&nbsp;25</U>, a notice of such proposed action, which shall specify the record date for the purposes of such stock
dividend, distribution of rights or warrants, or the date on which such reclassification, consolidation, merger, sale, transfer, liquidation, dissolution, or winding up is to take place and the date of participation therein by the holders of the
Series A Preferred and/or Common Stock, if any such date is to be fixed, and such notice shall be so given in the case of any action covered by clause (a)&nbsp;or (b) above at least ten (10)&nbsp;days prior to the record date for determining holders
of the Series A Preferred for purposes of such action, and in the case of any such other action, at least ten (10)&nbsp;days prior to the date of the taking of such proposed action or the date of participation therein by the holders of the Series A
Preferred and/or Common Stock, whichever shall be the earlier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In case any event set forth in <U>Section</U><U></U><U>&nbsp;11.1.2</U> or
<U>Section</U><U></U><U>&nbsp;13</U> shall occur, then, in any such case, (i)&nbsp;the Company shall as soon as practicable thereafter give to the Rights Agent and to each holder of a Right Certificate, in accordance with
<U>Section</U><U></U><U>&nbsp;25</U>, a notice of the occurrence of such event, which notice shall describe the event and the consequences of the event to holders of Rights under <U>Section</U><U></U><U>&nbsp;11.1.2</U> and
<U>Section</U><U></U><U>&nbsp;13</U>, and (ii)&nbsp;all references in this <U>Section</U><U></U><U>&nbsp;24</U> to Series A Preferred shall be deemed thereafter to refer to Common Stock and/or, if appropriate, other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;25. <U>Notices</U>. Notices or demands authorized by this Agreement to be given or made by the Rights Agent or by the holder of
any Right Certificate to or on the Company shall be sufficiently given or made if sent by overnight delivery service or first-class mail, postage prepaid, addressed (until another address is filed in writing with the Rights Agent) as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">AN2 Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1800 El Camino Real, Suite D </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94027 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the
provisions of <U>Section</U><U></U><U>&nbsp;21</U> and <U>Section</U><U></U><U>&nbsp;24</U>, any notice or demand authorized by this Agreement to be given or made by the Company or by the holder of any Right Certificate to or on the Rights Agent
shall be sufficiently given or made if sent by overnight delivery service or first-class mail, postage prepaid, addressed (until another address is filed in writing with the Company) as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Equiniti Trust Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">48 Wall Street, 22<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Relationship Management </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Equiniti Trust Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">48
Wall Street, 22<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>LegalTeamUS@equiniti.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices
or demands authorized by this Agreement to be given or made by the Company or the Rights Agent to the holder of any Right Certificate (or, prior to the Distribution Date, to the holder of any certificate representing Common Stock or of any Book
Entry Shares) shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company or the transfer agent or registrar for the Common
Stock; provided that prior to the Distribution Date a filing by the Company with the Securities and Exchange Commission shall constitute sufficient notice to the holders of securities of the Company, including the Rights, for purposes of this
Agreement and no other notice need be given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;26. <U>Supplements and Amendments</U>. For so long as the Rights are then
redeemable, the Company may in its sole and absolute discretion, and the Rights Agent shall, if the Company so directs, supplement or amend any provision of this Agreement in any respect without the approval of any holders of Rights or Common Stock.
From and after the time that the Rights are no longer redeemable, the Company may, and the Rights Agent shall, if the Company so directs, from time to time supplement or amend this Agreement without the approval of any holders of Rights (i)&nbsp;to
cure any ambiguity or to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein or (ii)&nbsp;to make any other changes or provisions in regard to matters or questions arising
hereunder which the Company may deem necessary or desirable, including but not limited to extending the Final Expiration Date; <I>provided, however,</I> that no such supplement or amendment shall adversely affect the interests of the holders of
Rights as such (other than an Acquiring Person or a Related Person of an Acquiring Person), and no such supplement or amendment may cause the Rights again to become redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or cause this Agreement again to become amendable as to an Acquiring Person or a Related Person of an Acquiring Person, other than in accordance with this sentence; <I>provided further,</I> that
the right of the Board to extend the Distribution Date shall not require any amendment or supplement hereunder. Upon the delivery of a certificate from an appropriate officer of the Company which states that the proposed supplement or amendment is
in compliance with the terms of this <U>Section</U><U></U><U>&nbsp;26</U>, the Rights Agent shall execute such supplement or amendment; <I>provided</I> that any supplement or amendment that does not amend <U>Sections 18</U>, <U>19</U>, <U>20</U> or
<U>21</U> hereof or this <U>Section</U><U></U><U>&nbsp;26</U> or any other Section of this Agreement in a manner adverse to the Rights Agent shall become effective immediately upon execution by the Company, whether or not also executed by the Rights
Agent. The Company shall promptly provide the Rights Agent with written notice of such supplement or amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;27.
<U>Exchange</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">27.1. <U>Exchange of Common Stock for Rights</U>. The Board may, at its option, at any time after the occurrence of a
Trigger Event, exchange Common Stock for all or part of the then outstanding and exercisable Rights (which shall not include Rights that have become void pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;11.1.2</U>) by exchanging at an
exchange ratio of one share of Common Stock per Right, appropriately adjusted to reflect any stock split, stock dividend or similar transaction occurring after the date hereof (such amount per Right being hereinafter referred to as the
&#147;<I>Exchange Consideration</I>&#148;). Notwithstanding the foregoing, the Board shall not be empowered to effect such exchange at any time after any Acquiring Person shall have become the Beneficial Owner of 50% or more of the Common Stock then
outstanding. From and after the occurrence of an event specified in <U>Section</U><U></U><U>&nbsp;13.1</U>, any Rights that theretofore have not been exchanged pursuant to this <U>Section</U><U></U><U>&nbsp;27.1</U> shall thereafter be exercisable
only in accordance with <U>Section</U><U></U><U>&nbsp;13</U> and may not be exchanged pursuant to this <U>Section</U><U></U><U>&nbsp;27.1</U>. The exchange of the Rights by the Board may be made effective at such time, on such basis and with such
conditions as the Board in its sole discretion may establish. Without limiting the foregoing, prior to effecting an exchange pursuant to this <U>Section</U><U></U><U>&nbsp;27</U>, the Board may direct the Company to enter into a Trust Agreement in
such form and with such terms as the Board shall then approve (the &#147;<I>Trust Agreement</I>&#148;). If the Board so directs, the Company shall enter into the Trust Agreement and shall issue to the trust created by such agreement (the
&#147;<I>Trust</I>&#148;) all of the Common Stock issuable pursuant to the exchange (or any portion thereof that has not theretofore been issued in connection with the exchange). From and after the time at which such shares are issued to the Trust,
all stockholders then entitled to receive shares pursuant to the exchange shall be entitled to receive such shares (and any dividends or distributions made thereon after the date on which such shares are deposited in the Trust) only from the Trust
and solely upon compliance with the relevant terms and provisions of the Trust Agreement. Any Common Stock or Series A Preferred issued at the direction of the Board in connection herewith shall be validly issued, fully paid and nonassessable Common
Stock or Series A Preferred (as the case may be), and the Company shall be deemed to have received as consideration for such issuance a benefit having a value that is at least equal to the aggregate par value of the shares so issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">27.2. <U>Exchange Procedures</U>. Immediately upon the effectiveness of the action of the
Board ordering the exchange for any Rights pursuant to <U>Section</U><U></U><U>&nbsp;27.1</U> and without any further action and without any notice, the right to exercise such Rights shall terminate and the only right thereafter of a holder of such
Rights shall be to receive the Exchange Consideration. The Company shall promptly give public notice of any such exchange; <I>provided, however,</I> that the failure to give, or any defect in, such notice shall not affect the validity of such
exchange. The Company promptly shall mail a notice of any such exchange to all of the holders of such Rights at their last addresses as they appear upon the registry books of the Rights Agent. Any notice which is mailed in the manner herein provided
shall be deemed given, whether or not the holder receives the notice. Each such notice of exchange shall state the method by which the exchange of the Common Stock for Rights will be effected and, in the event of any partial exchange, the number of
Rights which will be exchanged. Any partial exchange shall be effected pro rata based on the number of Rights (other than the Rights that have become void pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;11.1.2</U>) held by each holder of
Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">27.3. <U>Insufficient Shares</U>. The Company may at its option substitute, for each share of Common Stock that would otherwise be
issuable upon exchange of a Right, (i)&nbsp;a number of shares of Series A Preferred or fraction thereof (or equivalent preferred stock, as such term is defined in <U>Section</U><U></U><U>&nbsp;11.2</U>), (ii) cash, (iii)&nbsp;other equity
securities of the Company or common stock equivalents, as such term is defined in <U>Section</U><U></U><U>&nbsp;11.1.3</U>), (iv) debt securities of the Company, (v)&nbsp;other assets or (vi)&nbsp;any combination of the foregoing, in each case
having an aggregate value equal to the current per share market price of one share of Common Stock (determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U>) as of the date of such exchange. In the event that there shall not be sufficient
shares of Common Stock issued but not outstanding or authorized but unissued and otherwise available for issuance to permit an exchange of Rights for Common Stock as contemplated in accordance with this <U>Section</U><U></U><U>&nbsp;27</U>, the
Company shall substitute to the extent of such insufficiency, for each share of Common Stock that would otherwise be issuable upon exchange of a Right, consideration of any type described in <U>Section</U><U></U><U>&nbsp;11.1.3(B)(1)-(7)</U>, which
consideration shall have an aggregate current per share market price (determined pursuant to <U>Section</U><U></U><U>&nbsp;11.4</U> hereof) equal to the current per share market price of one share of Common Stock (determined pursuant to
<U>Section</U><U></U><U>&nbsp;11.4</U> hereof) as of the date of such exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;28. <U>Successors</U>. All the covenants and
provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective successors and assigns hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;29. <U>Benefits of this Agreement</U>. Nothing in this Agreement shall be construed to give to any Person or corporation other
than the Company, the Rights Agent and the registered holders of the Right Certificates (and, prior to the Distribution Date, the Common Stock) any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the
sole and exclusive benefit of the Company, the Rights Agent and the registered holders of the Right Certificates (and, prior to the Distribution Date, the Common Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;30. <U>Determination and Actions by the Board or Committee Thereof</U>. The Board, or a duly authorized committee thereof, shall
have the exclusive power and authority to administer this Agreement and to exercise the rights and powers specifically granted to the Board or to the Company, or as may be necessary or advisable in the administration of this Agreement, including,
without limitation, the right and power to (i)&nbsp;interpret the provisions of this Agreement and (ii)&nbsp;make all determinations deemed necessary or advisable for the administration of this Agreement (including, without limitation, a
determination to redeem or not redeem the Rights or amend this Agreement). In administering this Agreement and exercising the rights and powers specifically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted to the Board and to the Company hereunder, and in interpreting this Agreement and making any determination hereunder, the Board, or a duly authorized committee thereof, may consider any
and all facts, circumstances or information it deems to be necessary, useful or appropriate. All such actions, calculations, interpretations and determinations that are done or made by the Board, or a duly authorized committee thereof, in good faith
shall be final, conclusive and binding on the Company, the Rights Agent, the holders of the Rights, as such, and all other parties to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;31. <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or
invalidated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;32. <U>Governing Law</U>. This Agreement and each Right Certificate issued hereunder shall be deemed to be a
contract made under the internal laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;33. <U>Counterparts</U>. This Agreement may be executed in any number of counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. A signature to this Agreement transmitted electronically shall have the same authority, effect and enforceability as an
original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;34. <U>Descriptive Headings</U>. Descriptive headings of the several Sections of this Agreement are
inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature
Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of
the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AN2 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Easom</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Eric Easom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EQUINITI TRUST COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam E. Burke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Adam E. Burke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: EVP, Chief Customer Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Rights Plan</I>] </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF
DESIGNATIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SERIES A
JUNIOR PARTICIPATING PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">AN2 THERAPEUTICS, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant
to Section&nbsp;151 of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delaware General Corporation Law) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AN2 Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called
the &#147;<I>Corporation</I>&#148;), hereby certifies that the following resolution was adopted by the Board of Directors of the Corporation (hereinafter called the &#147;<I>Board of Directors</I>&#148; or the &#147;<I>Board</I>&#148;) as required
by Section&nbsp;151 of the General Corporation Law at a meeting duly called and held on August&nbsp;15, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">RESOLVED, that pursuant to
the authority expressly granted to and vested in the Board in accordance with the provisions of the Amended and Restated Certificate of Incorporation of the Corporation, the Board hereby creates a series of Preferred Stock, par value $0.00001 per
share (the &#147;<I>Preferred Stock</I>&#148;), of the Corporation and hereby states the designation and number of shares, and fixes the relative rights, powers and preferences, and qualifications, limitations and restrictions thereof as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Designation and Amount</U>. The shares of such series shall be designated as &#147;Series A Junior Participating
Preferred Stock&#148; (the &#147;<I>Series A Preferred</I>&#148;) and the number of shares constituting the Series A Preferred shall be 500,000. Such number of shares may be increased or decreased by resolution of the Board of Directors;
<B><I>provided,</I></B> that no decrease shall reduce the number of shares of Series A Preferred to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options,
rights or warrants or upon the conversion of any outstanding securities issued by the Corporation convertible into Series A Preferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Dividends and Distributions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Subject to the prior and superior rights of the holders of any shares of any class or series of stock of this Corporation
ranking prior and superior to the Series A Preferred with respect to dividends, the holders of shares of Series A Preferred, in preference to the holders of Common Stock, par value $0.00001 per share (the &#147;<I>Common Stock</I>&#148;), of the
Corporation, and of any other stock ranking junior to the Series A Preferred, shall be entitled to receive, when, as and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash on the
first day of March, June, September and December in each year (each such date being referred to herein as a &#147;<I>Quarterly Dividend Payment Date</I>&#148;), commencing on the first Quarterly Dividend Payment Date after the first issuance of a
share or fraction of a share of Series A Preferred, in an amount per share (rounded to the nearest cent) equal to the greater of (a) $1.00 or (b)&nbsp;subject to the provision for adjustment hereinafter set forth, 1,000 times the aggregate per share
amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all <FONT STYLE="white-space:nowrap">non-cash</FONT> dividends or other distributions, other than a dividend payable in shares of Common Stock or a
subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date or, with respect to the first Quarterly Dividend Payment Date,
since the first issuance of any share or fraction of a share of Series A Preferred. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision,
combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the
amount to which holders of shares of Series A Preferred were entitled immediately prior to such event under clause (b)&nbsp;of the preceding sentence shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of
shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Corporation shall declare a dividend or distribution on the Series A Preferred as provided in paragraph (A)&nbsp;of
this <U>Section</U><U></U><U>&nbsp;2</U> immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock); provided that, in the event no dividend or distribution shall have been
declared on the Common Stock during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, a dividend of $1.00 per share on the Series A Preferred shall nevertheless be payable when, as and if
declared by the Board of Directors, in accordance with paragraph (A)&nbsp;above on such subsequent Quarterly Dividend Payment Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Dividends shall begin to accrue and be cumulative on outstanding shares of Series A Preferred from the Quarterly Dividend
Payment Date next preceding the date of issue of such shares, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such shares shall begin to accrue from the
date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series A Preferred entitled to receive a quarterly dividend and before
such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue and be cumulative from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends paid on the shares of
Series A Preferred in an amount less than the total amount of such dividends at the time accrued and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
payable on such shares shall be allocated pro rata on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">share-by-share</FONT></FONT> basis among all such shares at the time
outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series A Preferred entitled to receive payment of a dividend or distribution declared thereon, which record date shall be not more than sixty
(60)&nbsp;days prior to the date fixed for the payment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Voting Rights</U>. The holders of shares of Series A
Preferred shall have the following voting rights: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Subject to the provision for adjustment hereinafter set forth, each
share of Series A Preferred shall entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the shareholders of the Corporation. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock
payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser
number of shares of Common Stock, then in each such case the number of votes per share to which holders of shares of Series A Preferred were entitled immediately prior to such event shall be adjusted by multiplying such number by a fraction, the
numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Except as otherwise provided herein, in any other Certificate of Designations creating a series of Preferred Stock or any
similar stock, or by law, the holders of shares of Series A Preferred and the holders of shares of Common Stock and any other capital stock of the Corporation having general voting rights shall vote together as one class on all matters submitted to
a vote of shareholders of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Except as set forth herein, or as otherwise provided by law, holders of
Series A Preferred shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) If, at the time of any annual meeting of stockholders for the election of directors, the equivalent of six quarterly
dividends (whether or not consecutive) payable on any share or shares of Series A Preferred are in default, the number of directors constituting the Board of Directors of the Corporation shall be increased by two. In addition to voting together with
the holders of Common Stock for the election of other directors of the Corporation, the holders of record of the Series A Preferred, voting separately as a class to the exclusion of the holders of Common Stock, shall be entitled at such meeting of
stockholders (and at each subsequent annual meeting of stockholders), unless all dividends in arrears on the Series A Preferred have been paid or declared and set apart for payment prior thereto, to vote for the election of two directors of the
Corporation, the holders of any Series A Preferred being entitled to cast a number of votes per share of Series A Preferred as is specified in paragraph (A)&nbsp;of this <U>Section</U><U></U><U>&nbsp;3</U>. Each such additional director shall serve
until the next annual meeting of stockholders for the election of directors, or until his successor shall be elected and shall qualify, or until his right to hold </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such office terminates pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;3(D)</U>. Until the default in payments of all dividends which permitted the election of said directors
shall cease to exist, any director who shall have been so elected pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;3(D)</U> may be removed at any time, without cause, only by the affirmative vote of the holders of the shares of
Series A Preferred at the time entitled to cast a majority of the votes entitled to be cast for the election of any such director at a special meeting of such holders called for that purpose, and any vacancy thereby created may be filled by the vote
of such holders. If and when such default shall cease to exist, the holders of the Series A Preferred shall be divested of the foregoing special voting rights, subject to revesting in the event of each and every subsequent like default in payments
of dividends. Upon the termination of the foregoing special voting rights, the terms of office of all persons who may have been elected directors pursuant to said special voting rights shall forthwith terminate, and the number of directors
constituting the Board of Directors shall be reduced by two. The voting rights granted by this <U>Section</U><U></U><U>&nbsp;3(D)</U> shall be in addition to any other voting rights granted to the holders of the Series A Preferred in this
<U>Section</U><U></U><U>&nbsp;3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Certain Restrictions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Whenever quarterly dividends or other dividends or distributions payable on the Series A Preferred as provided in
<U>Section</U><U></U><U>&nbsp;2</U> are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series A Preferred outstanding shall have been paid in full, the Corporation shall
not: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) declare or pay dividends, or make any other distributions, on any shares of stock ranking junior (either as to
dividends or upon liquidation, dissolution or winding up) to the Series A Preferred; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) declare or pay dividends, or
make any other distributions, on any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred, except dividends paid ratably on the Series A Preferred and all such parity
stock on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) redeem or purchase or otherwise acquire for consideration shares of any stock ranking junior (either as to dividends or
upon liquidation, dissolution or winding up) to the Series A Preferred, provided that the Corporation may at any time redeem, purchase or otherwise acquire shares of any such junior stock in exchange for shares of any stock of the Corporation
ranking junior (both as to dividends and upon dissolution, liquidation or winding up) to the Series A Preferred; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
redeem or purchase or otherwise acquire for consideration any shares of Series A Preferred, or any shares of stock ranking on a parity with the Series A Preferred, except in accordance with a purchase offer made in writing or by publication (as
determined by the Board of Directors) to all holders of such shares upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and
classes, shall determine in good faith will result in fair and equitable treatment among the respective series or classes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) The Corporation shall not permit any subsidiary of the Corporation to
purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (A)&nbsp;of this <U>Section</U><U></U><U>&nbsp;4</U>, purchase or otherwise acquire such shares at such time and in
such manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Reacquired Shares</U>. Any shares of Series A Preferred purchased or otherwise acquired by the
Corporation in any manner whatsoever shall be retired and canceled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of Preferred Stock and may be reissued as part of a new
series of Preferred Stock subject to the conditions and restrictions on issuance set forth herein, in the Amended and Restated Certificate of Incorporation of the Corporation or in any other Certificate of Designations creating a series of Preferred
Stock or any similar stock or as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Liquidation, Dissolution or Winding Up</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Upon any liquidation, dissolution or winding up of the Corporation, voluntary or otherwise no distribution shall be made
(i)&nbsp;to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Preferred unless, prior thereto, the holders of Series A Preferred shall have received an amount per
share (the &#147;<I>Series A Preferred Liquidation Preference</I>&#148;) equal to $1,000 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment, provided that
the holders of shares of Series A Preferred shall be entitled to receive an aggregate amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the aggregate amount to be distributed per share to holders
of Common Stock, or (ii)&nbsp;to the holders of shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred, except distributions made ratably on the Series A Preferred and
all such parity stock in proportion to the total amounts to which the holders of all such shares are entitled upon such liquidation, dissolution or winding up. In the event the Corporation shall at any time declare or pay any dividend on the Common
Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or
lesser number of shares of Common Stock, then in each such case the aggregate amount to which holders of Series A Preferred were entitled immediately prior to such event under the proviso in clause (i)&nbsp;of the preceding sentence shall be
adjusted by multiplying such amount by a fraction the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that are outstanding
immediately prior to such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) In the event, however, that there are not sufficient assets available to
permit payment in full of the Series A Preferred Liquidation Preference and the liquidation preferences of all other classes and series of stock of the Corporation, if any, that rank on a parity with the Series A Preferred in respect thereof, then
the assets available for such distribution shall be distributed ratably to the holders of the Series A Preferred and the holders of such parity shares in proportion to their respective liquidation preferences. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) Neither the merger or consolidation of the Corporation into or with another corporation nor the merger or consolidation of
any other corporation into or with the Corporation shall be deemed to be a liquidation, dissolution or winding up of the Corporation within the meaning of this <U>Section</U><U></U><U>&nbsp;6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Consolidation, Merger, etc</U>. In case the Corporation shall enter into any consolidation, merger, combination or other
transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case each share of Series A Preferred shall at the same time be similarly exchanged or
changed into an amount per share, subject to the provision for adjustment hereinafter set forth, equal to 1,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, into which or for
which each share of Common Stock is changed or exchanged. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the
outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the amount set forth in the preceding
sentence with respect to the exchange or change of shares of Series A Preferred shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately after such event and
the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.
<U>No Redemption</U>. The Series A Preferred shall not be redeemable by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Rank</U>. The Series A
Preferred shall rank, with respect to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up, junior to all series of any other class of the Corporation&#146;s Preferred Stock, except to the extent that
any such other series specifically provides that it shall rank on a parity with or junior to the Series A Preferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.
<U>Amendment</U>. At any time any shares of Series A Preferred are outstanding, the Amended and Restated Certificate of Incorporation of the Corporation shall not be further amended in any manner which would materially alter or change the powers,
preferences or special rights of the Series A Preferred so as to affect them adversely without the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of Series A Preferred, voting
separately as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Fractional Shares</U>. Series A Preferred may be issued in fractions of a share that
shall entitle the holder, in proportion to such holder&#146;s fractional shares, to exercise voting rights, receive dividends, participate in distributions and to have the benefit of all other rights of holders of Series A Preferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A- 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Form of Right Certificate] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificate No. <FONT STYLE="white-space:nowrap">R-</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">_______ Rights</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">NOT EXERCISABLE AFTER August&nbsp;15, 2025 OR EARLIER IF NOTICE OF REDEMPTION OR EXCHANGE IS GIVEN OR IF THE
COMPANY IS MERGED OR ACQUIRED PURSUANT TO AN AGREEMENT OF THE TYPE DESCRIBED IN SECTION 13.3<B> </B>OF THE AGREEMENT. THE RIGHTS ARE SUBJECT TO REDEMPTION AT $0.01 PER RIGHT, AND TO EXCHANGE ON THE TERMS SET FORTH IN THE AGREEMENT. <U>UNDER CERTAIN
CIRCUMSTANCES (SPECIFIED IN SECTION 11.1.2 OF THE AGREEMENT), RIGHTS BENEFICIALLY OWNED BY OR TRANSFERRED TO AN ACQUIRING PERSON (AS DEFINED IN THE AGREEMENT), OR ANY SUBSEQUENT HOLDER OF SUCH RIGHTS, WILL BECOME NULL AND VOID AND WILL NO LONGER BE
TRANSFERABLE</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Right Certificate </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AN2 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This certifies that ________________, or registered assigns, is the registered owner of the number of Rights set forth above, each of which
entitles the owner thereof, subject to the terms, provisions and conditions of the Rights Agreement, dated as of August&nbsp;15, 2024, as the same may be amended from time to time (the &#147;<I>Agreement</I>&#148;), between AN2 Therapeutics, Inc., a
Delaware corporation (the &#147;<I>Company</I>&#148;), and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent (the &#147;<I>Rights Agent</I>&#148;), to purchase from the Company at any time after the
Distribution Date and prior to 5:00 P.M. (New York time) on August&nbsp;15, 2025, at the offices of the Rights Agent, or its successors as Rights Agent, designated for such purpose, one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a
fully paid, nonassessable share of Series A Junior Participating Preferred Stock, par value $0.00001 per share (the &#147;<I>Series A Preferred</I>&#148;), of the Company, at a purchase price of $6.50 per one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred, subject to adjustment (the &#147;<I>Purchase Price</I>&#148;), upon presentation and surrender of this Right Certificate with the Form of Election to Purchase
and certification duly executed. The number of Rights evidenced by this Right Certificate (and the number of <FONT STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred which may be purchased upon exercise thereof) set
forth above, and the Purchase Price set forth above, are the number and Purchase Price as of August&nbsp;15, 2024, based on the Series A Preferred as constituted at such date. Capitalized terms used in this Right Certificate without definition shall
have the meanings ascribed to them in the Agreement. As provided in the Agreement, the Purchase Price and the number of shares of Series A Preferred which may be purchased upon the exercise of the Rights evidenced by this Right Certificate are
subject to modification and adjustment upon the happening of certain events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Right Certificate is subject to all of the terms,
provisions and conditions of the Agreement, which terms, provisions and conditions are hereby incorporated herein by reference and made a part hereof and to which Agreement reference is hereby made for a full description of the rights, limitations
of rights, obligations, duties and immunities hereunder of the Rights Agent, the Company and the holders of the Right Certificates. Copies of the Agreement are on file at the principal offices of the Company and the Rights Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Right Certificate, with or without other Right Certificates, upon surrender at the
offices of the Rights Agent designated for such purpose, may be exchanged for another Right Certificate or Right Certificates of like tenor and date evidencing Rights entitling the holder to purchase a like aggregate number of <FONT
STYLE="white-space:nowrap">one-thousandths</FONT> of a share of Series A Preferred as the Rights evidenced by the Right Certificate or Right Certificates surrendered shall have entitled such holder to purchase. If this Right Certificate shall be
exercised in part, the holder shall be entitled to receive upon surrender hereof another Right Certificate or Right Certificates for the number of whole Rights not exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Agreement, the Board may, at its option, (i)&nbsp;redeem the Rights evidenced by this Right Certificate at a
redemption price of $0.01 per Right or (ii)&nbsp;exchange Common Stock for the Rights evidenced by this Certificate, in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No fractional Series A Preferred will be issued upon the exercise of any Right or Rights evidenced hereby (other than fractions of Series A
Preferred which are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred, which may, at the election of the Company, be evidenced by depository receipts), but in lieu thereof a cash
payment will be made, as provided in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No holder of this Right Certificate, as such, shall be entitled to vote or receive
dividends or be deemed for any purpose the holder of the Series A Preferred or of any other securities of the Company which may at any time be issuable on the exercise hereof, nor shall anything contained in the Agreement or herein be construed to
confer upon the holder hereof, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any
corporate action, or to receive notice of meetings or other actions affecting stockholders (except as provided in the Agreement), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by this Right
Certificate shall have been exercised as provided in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If any term, provision, covenant or restriction of the Agreement is
held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of the Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Right Certificate shall not be valid or binding for any purpose until it shall have been
countersigned by the Rights Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WITNESS the facsimile signature of the proper officers of the Company and its corporate
seal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated as of __________, 202_. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attest:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AN2 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Countersigned:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EQUINITI TRUST COMPANY, LLC</B>,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as Rights Agent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of Reverse Side of Right Certificate </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF ASSIGNMENT </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be
executed by the registered holder if such holder </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">desires to transfer the Right Certificate.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR&nbsp;VALUE&nbsp;RECEIVED&nbsp;
<U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereby&nbsp;sells,&nbsp;assigns&nbsp;and&nbsp;transfers&nbsp;unto&nbsp;
<U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U>&#8195; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Please print name and address </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of transferee) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights evidenced by this Right
Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint <U></U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> Attorney, to transfer the within Right Certificate on the books of the
within-named Company, with full power of substitution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:<U> </U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Medallion Guaranteed:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Signatures must be guaranteed by an &#147;eligible guarantor institution&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">17Ad-15</FONT> promulgated under the Securities Exchange Act of 1934, as amended, which is a member of a recognized Medallion Signature Guarantee Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby certifies that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) the Rights evidenced by this Right Certificate are not Beneficially Owned by and are not being assigned to an Acquiring Person or a
Related Person of an Acquiring Person; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) after due inquiry and to the best knowledge of the undersigned, the undersigned did not
acquire the Rights evidenced by this Right Certificate from any Person who is, was or subsequently became an Acquiring Person or a Related Person of an Acquiring Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:<U> </U><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF ELECTION TO PURCHASE </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed if holder desires to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">exercise the Right Certificate.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: AN2
Therapeutics, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably elects to exercise __________________ Rights represented by this Right Certificate
to purchase the Series A Preferred issuable upon the exercise of such Rights (or such other securities or property of the Company or of any other Person which may be issuable upon the exercise of the Rights) and requests that certificates for such
stock (or such other securities or property of the Company or of any other Person which may be issuable upon the exercise of the Rights) be issued in the name of (or to, as the case may be): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Please print name and address) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If such number of Rights shall not be all the Rights evidenced by this Right Certificate, a new Right Certificate for the balance remaining of such
Rights shall be registered in the name of and delivered to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please insert social security </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or other identifying number____________________________________________________ </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(Please print name and address) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: __________________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Medallion Guaranteed:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Signatures must be guaranteed by an &#147;eligible guarantor institution&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">17Ad-15</FONT> promulgated under the Securities Exchange Act of 1934, as amended, which is a member of a recognized Medallion Signature Guarantee Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby certifies that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) the Rights evidenced by this Right Certificate are not Beneficially Owned by and are not being assigned to an Acquiring Person or a
Related Person of an Acquiring Person; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) after due inquiry and to the best knowledge of the undersigned, the undersigned did not
acquire the Rights evidenced by this Right Certificate from any Person who is, was or subsequently became an Acquiring Person or a Related Person of an Acquiring Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:_______________ </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The signature in the foregoing Form of Assignment and Form of Election to Purchase must conform to the name as written upon the face of this
Right Certificate in every particular, without alteration or enlargement or any change whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event the certification set
forth above in the Form of Assignment or Form of Election to Purchase is not completed, the Company will deem the Beneficial Owner of the Rights evidenced by this Right Certificate to be an Acquiring Person or a Related Person of an Acquiring Person
and such Assignment or Election to Purchase will not be honored. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>As described in the Rights Agreement, Rights which are </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>held by or have been held by an Acquiring Person or any Related Persons of an Acquiring</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Person (as such terms are defined in the Rights Agreement) and certain transferees thereof shall</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>become null and void and will no longer be transferable</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SUMMARY OF RIGHTS TO PURCHASE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PREFERRED STOCK </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On
August&nbsp;15, 2024 the Board of Directors of AN2 Therapeutics, Inc. (the &#147;<I>Company</I>&#148;) declared a dividend of one preferred stock purchase right (a &#147;<I>Right</I>&#148;) for each share of Common Stock, par value $0.00001 (the
&#147;<I>Common Stock</I>&#148;), of the Company outstanding at the close of business on August&nbsp;29, 2024 (the &#147;<I>Record Date</I>&#148;). As long as the Rights are attached to the Common Stock, the Company will issue one Right (subject to
adjustment) with each new share of Common Stock so that all such shares will have attached Rights. When exercisable, each Right will entitle the registered holder to purchase from the Company one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Junior Participating Preferred Stock (the &#147;<I>Series A Preferred</I>&#148;) of the Company at a price of $6.50 per one
<FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred, subject to certain anti-dilution adjustments (the &#147;<I>Purchase Price</I>&#148;). The description and terms of the Rights are set forth in a Rights
Agreement, dated as of August&nbsp;15, 2024, as the same may be amended from time to time (the &#147;<I>Agreement</I>&#148;), between the Company and Equiniti Trust Company, LLC, as Rights Agent (the &#147;<I>Rights Agent</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Until the earlier to occur of (i)&nbsp;the close of business on the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) business
day following a public announcement that a person or group of affiliated or associated persons has acquired, or obtained the right to acquire, beneficial ownership of 20% or more of the Common Stock including certain synthetic equity positions
created by derivative securities, which are treated as beneficial ownership of the number of shares of Common Stock equivalent to the economic exposure created by the synthetic equity position, to the extent actual shares of Common Stock are
directly or indirectly beneficially owned by a counterparty to the synthetic equity position) (an &#147;<I>Acquiring Person</I>&#148;) or (ii)&nbsp;the close of business on the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>)
business day (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated persons becomes an Acquiring Person) following the commencement or announcement of an intention to make
a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 20% or more of the Common Stock (the earlier of (i)&nbsp;and (ii) being called the &#147;<I>Distribution Date</I>&#148;), the
Rights will be evidenced, with respect to any of the Common Stock certificates outstanding as of the Record Date, by such Common Stock certificates or, with respect to any uncertificated Common Stock registered in book entry form, by notation in
book entry, in either case together with a copy of this Summary of Rights. The Agreement provides that any person who beneficially owned 20% or more of the Common Stock immediately prior to the first public announcement of the adoption of the
Agreement, together with any affiliates and associates of that person (each an &#147;<I>Existing Holder</I>&#148;), shall not be deemed to be an &#147;Acquiring Person&#148; for purposes of the Agreement unless the Existing Holder becomes the
beneficial owner of one or more additional shares of Common Stock (other than pursuant to a dividend or distribution paid or made by the Company on the outstanding Common Stock in Common Stock or pursuant to a split or subdivision of the outstanding
Common Stock). However, if upon acquiring beneficial ownership of one or more additional shares of Common Stock, the Existing Holder does not beneficially own 20% or more of the Common Stock then outstanding, the Existing Holder shall not be deemed
to be an &#147;Acquiring Person&#148; for purposes of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Agreement provides that until the Distribution Date (or earlier redemption, exchange,
termination or expiration of the Rights), the Rights will be transferred with and only with the Common Stock. Until the Distribution Date (or earlier redemption, exchange, termination or expiration of the Rights), new Common Stock certificates
issued after the close of business on the Record Date upon transfer or new issuance of the Common Stock will contain a notation incorporating the Agreement by reference, and the Company will deliver a notice to that effect upon the transfer or new
issuance of book entry shares. Until the Distribution Date (or earlier redemption, exchange, termination or expiration of the Rights), the surrender for transfer of any certificates for Common Stock or any book entry shares, with or without such
notation, notice or a copy of this Summary of Rights, will also constitute the transfer of the Rights associated with the Common Stock represented by such certificate or the book entry shares. As soon as practicable following the Distribution Date,
separate certificates evidencing the Rights (&#147;<I>Right Certificates</I>&#148;) will be mailed to holders of record of the Common Stock as of the close of business on the Distribution Date and such separate Right Certificates alone will evidence
the Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Rights are not exercisable until the Distribution Date. The Rights will expire on August&nbsp;15, 2025, subject to the
Company&#146;s right to extend such date (the &#147;<I>Final Expiration Date</I>&#148;), unless earlier redeemed or exchanged by the Company or terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each share of Series A Preferred purchasable upon exercise of the Rights will be entitled, when, as and if declared, to a minimum preferential
quarterly dividend payment of $1.00 per share or, if greater, an aggregate dividend of 1,000 times the dividend, if any, declared per share of Common Stock. In the event of liquidation, dissolution or winding up of the Company, the holders of the
Series A Preferred will be entitled to a minimum preferential liquidation payment of $1,000 per share (plus any accrued but unpaid dividends), provided that such holders of the Series A Preferred will be entitled to an aggregate payment of 1,000
times the payment made per share of Common Stock. Each share of Series A Preferred will have 1,000 votes and will vote together with the Common Stock. Finally, in the event of any merger, consolidation or other transaction in which shares of Common
Stock are exchanged, each share of Series A Preferred will be entitled to receive 1,000 times the amount received per share of Common Stock. Series A Preferred will not be redeemable. These rights are protected by customary antidilution provisions.
Because of the nature of the Series A Preferred&#146;s dividend, liquidation and voting rights, the value of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred purchasable upon exercise of each Right should
approximate the value of one share of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Purchase Price payable, and the number of shares of Series A Preferred or other
securities or property issuable, upon exercise of the Rights are subject to adjustment from time to time to prevent dilution (i)&nbsp;in the event of a stock dividend on, or a subdivision, combination or reclassification of the Series A Preferred,
(ii)&nbsp;upon the grant to holders of the Series A Preferred of certain rights or warrants to subscribe for or purchase Series A Preferred or convertible securities at less than the current market price of the Series A Preferred or (iii)&nbsp;upon
the distribution to holders of the Series A Preferred of evidences of indebtedness, cash, securities or assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(excluding regular periodic cash dividends at a rate not in excess of 125% of the rate of the last regular periodic cash dividend theretofore paid or, in case regular periodic cash dividends have
not theretofore been paid, at a rate not in excess of 50% of the average net income per share of the Company for the four quarters ended immediately prior to the payment of such dividend, or dividends payable in Series A Preferred (which dividends
will be subject to the adjustment described in clause (i)&nbsp;above)) or of subscription rights or warrants (other than those referred to above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event that a Person becomes an Acquiring Person or if the Company were the surviving corporation in a merger with an Acquiring Person
or any affiliate or associate of an Acquiring Person and shares of the Common Stock were not changed or exchanged, each holder of a Right, other than Rights that are or were acquired or beneficially owned by the Acquiring Person (which Rights will
thereafter be void), will thereafter have the right to receive upon exercise that number of shares of Common Stock having a market value of two times the then current Purchase Price of the Right. In the event that, after a Person has become an
Acquiring Person, the Company were acquired in a merger or other business combination transaction or more than 50% of its assets or earning power were sold, proper provision shall be made so that each holder of a Right shall thereafter have the
right to receive, upon the exercise thereof at the then current Purchase Price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction would have a market value of two times the then current
Purchase Price of the Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At any time after a Person becomes an Acquiring Person and prior to the earlier of one of the events
described in the last sentence of the previous paragraph or the acquisition by such Acquiring Person of 50% or more of the then outstanding Common Stock, the Board of Directors may cause the Company to exchange the Rights (other than Rights owned by
an Acquiring Person which will have become void), in whole or in part, for shares of Common Stock at an exchange rate of one share of Common Stock per Right (subject to adjustment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No adjustment in the Purchase Price will be required until cumulative adjustments require an adjustment of at least 1% in such Purchase Price.
No fractional Series A Preferred or Common Stock will be issued (other than fractions of Series A Preferred which are integral multiples of one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of Series A Preferred, which may, at
the election of the Company, be evidenced by depository receipts), and in lieu thereof, a payment in cash will be made based on the market price of the Series A Preferred or Common Stock on the last trading date prior to the date of exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Rights may be redeemed in whole, but not in part, at a price of $0.01 per Right (the &#147;<I>Redemption Price</I>&#148;) by the Board of
Directors at any time prior to the time that an Acquiring Person has become such. The redemption of the Rights may be made effective at such time, on such basis and with such conditions as the Board of Directors in its sole discretion may establish.
Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder of the Company beyond those as an existing
stockholder, including, without limitation, the right to vote or to receive dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any of the provisions of the Agreement may be amended by the Board of Directors, or a duly
authorized committee thereof, for so long as the Rights are then redeemable, and after the Rights are no longer redeemable, the Company may amend or supplement the Agreement in any manner that does not adversely affect the interests of the holders
of the Rights (other than an Acquiring Person or any affiliate or associate of an Acquiring Person). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A copy of the Agreement has been
filed with the Securities and Exchange Commission as an Exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> A copy of the Agreement is available free of charge from the Company. This summary description of the Rights
does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d879523dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1%">


<IMG SRC="g879523g0818100647176.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 16, 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MENLO PARK, Calif.&#151;(BUSINESS <FONT
STYLE="white-space:nowrap">WIRE)--Aug.</FONT> 16, 2024&#151; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today
announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recently became
aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14,
2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all stockholders of the Company and ensure that the Board remains in the best position to discharge its fiduciary duties to the Company and
its stockholders. The rights plan will guard against efforts to capitalize on the recent share price of the Company through open market accumulations and other coercive tactics aimed at gaining control of the Company without paying all stockholders
a full control premium for their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the plan, one preferred stock purchase right will be distributed for each share of common stock held by
stockholders of record on August 29, 2024. Under certain circumstances, each right will entitle stockholders to buy one <FONT STYLE="white-space:nowrap">one-thousandth</FONT> of a share of newly-created Series A Junior Participating Preferred Stock
of the Company at an exercise price of $6.50. The Company&#146;s Board of Directors will be entitled to redeem the rights at $0.01 per right at any time before a person or group has acquired 20% or more of the outstanding common stock. The rights
will expire on August 15, 2025, subject to the Company&#146;s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, if a person or group acquires 20% or more of the Company&#146;s common stock (including shares that are synthetically owned
pursuant to derivative transactions or ownership of derivative securities) or announces a tender offer and the consummation of that offer would result in such ownership (we refer to such a person or group as an &#147;acquiring person&#148;), each
right will entitle its holder to purchase, at the right&#146;s then-current exercise price, a number of shares of common stock having a market value at that time of twice the right&#146;s exercise price. Rights held by the acquiring person will
become void and will not be exercisable. If the Company is acquired in a merger or other business combination transaction that has not been approved by the Board of Directors after the rights become exercisable, each right will entitle its holder to
purchase, at the right&#146;s then-current exercise price, a number of shares of the acquiring company&#146;s common stock having a market value at that time of twice the right&#146;s exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dividend distribution to establish the new rights plan will be payable to stockholders of record on August 29, 2024. The rights distribution is not
taxable to stockholders. Further details about the rights plan will be contained in a Form 8-K to be filed by the Company with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AN2
Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics
derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, nontuberculous mycobacteria (NTM), and melioidosis, along with early-stage programs focused on targets in infectious diseases
and oncology. For more information, please visit our website at <U>www.an2therapeutics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
expressed or implied in this press release include, but are not limited to, statements regarding the purpose and objectives of the rights plan and other statements that are not historical fact. These statements are based on AN2&#146;s current
estimates, expectations, plans, objectives and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: threats intended to capitalize on the recent share price of the Company through open market
accumulations and other coercive tactics; potential disruptions related to AN2&#146;s restructuring plans and its ability to implement its plans for its internal boron chemistry platform and ongoing pipeline programs; timely enrollment of patients
in AN2&#146;s existing and future clinical trials; AN2&#146;s ability to procure sufficient supply of its product candidates for its existing and future clinical trials; the potential for results from clinical trials to differ from preclinical,
early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with AN2&#146;s product candidates; the significant uncertainty associated with AN2&#146;s product candidates ever
receiving any regulatory approvals; continued funding by the National Institute of Allergy and Infectious Disease (NIAID) of AN2&#146;s development program for melioidosis; AN2&#146;s ability to obtain, maintain or protect intellectual property
rights related to its current and future product candidates; implementation of AN2&#146;s strategic plans for its business and product candidates; the sufficiency of AN2&#146;s capital resources and need for additional capital to achieve its goals;
global macroeconomic conditions and global conflicts and other risks, including those described under the heading &#147;Risk Factors&#148; in AN2&#146;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and AN2&#146;s other reports
filed with the SEC. These filings, when made, are available on the investor relations section of AN2&#146;s website at <U>www.an2therapeutics.com</U> and on the SEC&#146;s website at <U>www.sec.go</U><U>v</U>. Forward-looking statements contained in
this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">View source version on <U>businesswire.com</U>:
<U>https://www.businesswire.com/news/home/20240816585924/en</U>/ </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucy O. Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>l.day@an2therapeutics.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anne Bowdidge </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>abowdidge@an2therapeutics.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: AN2 Therapeutics, Inc. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>antx-20240815.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/19/2024 8:46:16 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:antx="http://www.an2therapeutics.com/20240815"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.an2therapeutics.com/20240815"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antx-20240815_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antx-20240815_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="antx-20240815_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="antx_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="antx_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>antx-20240815_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/19/2024 8:46:19 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="antx-20240815.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="antx_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="antx_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="53.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="54.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="55.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>antx-20240815_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/19/2024 8:46:16 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="antx_DocumentAndEntityInformationTable" xlink:to="antx_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="antx_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="antx_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="antx_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="antx_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="antx_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>antx-20240815_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/19/2024 8:46:17 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="antx-20240815.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="antx_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="antx-20240815.xsd#antx_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="antx_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationTable" xlink:to="antx_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="54.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="antx_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="55.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g879523g0818100647176.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g879523g0818100647176.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E 0\# 2(  A$! Q$!_\0
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M ->J?RK+\<?#VR\9)%+YOV6]BX$X7.Y?0UNZ=I,NG>&[?2HKK;)# (EGV9Y
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MQ#>:G:6K!HK9U"KD=,\\UU/B;P_%XD\/SZ1),T$<NWYU7)&"#T_"@#GO$O\
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MM=,%Q]H\D$>9LVY_#)_G110!LYHS110 9HS110 9HS110 9HS110 9HS110
(9HS110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140690201135664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_antx_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001880438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 15,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AN2 THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-0606654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1800 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">331-9090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_antx_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_antx_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Series A Junior Participating Preferred Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_antx_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">antx_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>antx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSB^WC,)BPSP WZ^%T"\WYA"V/$.?_ M02P,$%     @ G# 369^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ G# 360=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "<,!-9W<2UNN\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "<,!-9F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )PP
M$UF7 '2<+P4  $\7   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "<,!-9GZ ;\+$"  #B#   #0
M        @ %S#0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )PP$UF7BKL<
MP    !,"   +              "  4\0  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )PP$UD<.&7J/P$  #P"   /              "  3@1  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "<,!-9)!Z;HJT   #X 0  &@
M    @ &D$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "<,!-999!YDAD!  #/ P  $P              @ &)$P  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d879523d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>antx-20240815.xsd</File>
    <File>antx-20240815_def.xml</File>
    <File>antx-20240815_lab.xml</File>
    <File>antx-20240815_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d879523d8k.htm">d879523d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d879523d8k.htm": {
   "nsprefix": "antx",
   "nsuri": "http://www.an2therapeutics.com/20240815",
   "dts": {
    "schema": {
     "local": [
      "antx-20240815.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "antx-20240815_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "antx-20240815_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "antx-20240815_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d879523d8k.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-08-15_to_2024-08-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d879523d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-08-15_to_2024-08-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d879523d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "antx_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.an2therapeutics.com/20240815",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "antx_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.an2therapeutics.com/20240815",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.an2therapeutics.com//20240815/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-24-202430-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-202430-xbrl.zip
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M>?BB$KBURC/5OW7?5CL3V*U0-7C&DH!:/4G1M+I#^!O,L*8H5]SK%#UQGJ?
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ML%'T)MA)F [XH_DW<''$O)G_MNJ2OP%02P,$%     @ G# 361RDY&V<'P
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MC"X2Z7T]N@U4UF(@)Q,9T>^?Q60HXF> M &7N,*5F>\^S'<[#0,O2/0ZF!_
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M9)WA&BO$^!M1BTL4@&#I@3+%N=>"=4U"<SD%'^!EYN/\5Y_/G')W $XZA)4
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M4S"?H(]L'R\4(Y<+^,<X4EK9H,PM*!$<#G@ST85_6"0(&D]2. 0,V*#E!T8
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MWA+9&>T85H[&%FS@WT;0K8J*?KDH@)9P<0-[C*6YE9?!$8$4"'[F2V3>VJ[
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MY%S( 8GF \=%%.#959P<FD)\U[23V9X=3'N BX>=B%0,6X!1777JJ6:]KOW
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MN3O7%]\*DDA_[;W8P5[._T[U7^%5'8]\F<MP0-N5,!GIX"-1G2NHQC@V%PW
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M3M 3&+9'A2 [?1 9$BGJM[3<UH7X2?RCR[:[+F8*OXFP=_,F*JFA1&_U6MS
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M.-A[ZL-X"CEZ+[SY+,Y/^C#V:=O6DXI2/%2'9NL]DRU0> RL$8-:NK"</%:
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MK2@QNF?([GM6$8@]D'30 V51M-J0YXN!T2H"1M#*5-8$#GA&/((4R?WLIMQ
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MU8'O+NFG/.! ^2DN,>$.?R?#\B2<G=83B6-J$@46Z6I#IQ5G) ,/ N]+CE-
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M9H1-2476V#$/M)^SSW5!P_[00B\%WBI9Q1,:I;_67,.K@75!#9,AB'VU0>8
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M9G729?,2QQ_].WAA,A6ZFL_13!J/3KG(Q;] 9A9OZ5(5,%CG.\MD\BL:-:L
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M>;?,FXD$%ZU6CWHBIBR)!'*Y>?.NY[C;B3, Z"P[ S(RV3/.*2^ 5HN4W.T
M3C254Z==$$2%%86:*%ZK@%O#*G::>)O-F-K;%)SH\.MYP2:I Q/U;K)VOL9[
MI2TRQ4$!%I1?\NJ7"),92')#\("V/-^FS,\G&95^0)'N"9<^G4#!+J/"&!-T
MS#$)CW$B!1.[A(R,-14=_83:68*O.$;B\YK3R>PGTDS", 10WF;<\YQ@'373
M]KIUC%RB="HB0F(+DFVQA&+<$F$]5J<EE 4\/4H8C =II,%GV[+7HDLQKA7L
M0)?:78^#<?)*%,=>S,KH-C)WLFDL- "'>'Q1<,^L]%XZ5! [9*HY)X@,""2
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MR2TL6GGX?+P'Z*+8=?%M-_U1"^H%:L5YLAI@);54NV8=BX9#'"KT@CWT@F?
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MBYW-%]N91"CELPG8"10&9>_!:#8[LX?@-O6B=HK3GCJ:N\\9&?-:S^(YRL-
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M:*NE^SCWW'.%C][??C@?'KT_.SX=-AM'MZ/;\[/AV6^=@X-N_Z@7?L3S7KE
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MM$2%Y+<8NL1^YR?6":J4]!L-8ZGP(=R_*,8>[=* /<#\VFQL&6"W7+T\^H7
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M$GF8;5%FEZ>_XR%_(>P_4$L! A0#%     @ G# 36?2ZOLSI P  :@\  !$
M             ( !     &%N='@M,C R-# X,34N>'-D4$L! A0#%     @
MG# 360>O4-@)!@  "#D  !4              ( !& 0  &%N='@M,C R-# X
M,35?9&5F+GAM;%!+ 0(4 Q0    ( )PP$UE=?;: .P@  /E>   5
M      "  50*  !A;G1X+3(P,C0P.#$U7VQA8BYX;6Q02P$"% ,4    " "<
M,!-9+EX<2KX%  !4/0  %0              @ '"$@  86YT>"TR,#(T,#@Q
M-5]P<F4N>&UL4$L! A0#%     @ G# 361RDY&V<'P  -[<   X
M     ( !LQ@  &0X-SDU,C-D.&LN:'1M4$L! A0#%     @ G# 367SABVB1
M%P  ]'(  !               ( !>S@  &0X-SDU,C-D97@S,2YH=&U02P$"
M% ,4    " "<,!-9K%DLV^O!  !A-00 $               @ $Z4   9#@W
M.34R,V1E>#0Q+FAT;5!+ 0(4 Q0    ( )PP$UD=J--O] P  !<F   1
M          "  5,2 0!D.#<Y-3(S9&5X.3DQ+FAT;5!+!08     "  ( /\!
(  !V'P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d879523d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="antx-20240815.xsd" xlink:type="simple"/>
    <context id="duration_2024-08-15_to_2024-08-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001880438</identifier>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001880438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001880438</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-347">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-08-15_to_2024-08-15"
      id="Hidden_dei_EntityCentralIndexKey">0001880438</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2024-08-15_to_2024-08-15"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2024-08-15_to_2024-08-15">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-375">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-376">2024-08-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-377">AN2 THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-378">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-379">001-41331</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-380">82-0606654</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-381">1800 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-382">Suite D</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-383">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-384">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-385">94027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-386">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-387">331-9090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-388">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-389">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-390">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-391">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-392">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-393">ANTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-394">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember"
      id="ixv-395">Series A Junior Participating Preferred Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember"
      id="ixv-396">ANTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-08-15_to_2024-08-15_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember"
      id="ixv-397">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-398">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-08-15_to_2024-08-15" id="ixv-399">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
